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Slivka,	  Peter	  F.	  (Ph.D.,	  Chemistry)	  A	  Constrained	  Peptide	  that	  Targets	  the	  TLR4/MD2	  Interaction	  Investigating	  the	  Mechanism	  of	  Ultra-­‐stability	  in	  Bacterial	  Chemosensory	  Arrays	  Thesis	  directed	  by	  Professor	  Joseph	  J.	  Falke	  	   Pathological	  pain	  is	  a	  serious	  health	  problem	  that	  is	  initiated	  and	  perpetuated	  by	  Toll-­‐like	  Receptors	  (TLRs)	  on	  glial	  cells.	  Among	  the	  TLRs,	  Toll-­‐like	  Receptor	  4	  (TLR4)	  is	  one	  of	  most	  studied	  and	  most	  significant	  members	  of	  the	  TLR	  family	  that	  organizes	  an	  innate	  immune	  response	  by	  recognizing	  exogenous	  and	  endogenous	  danger	  signals.	  Specifically,	  TLR4	  recognizes	  lipopolysaccharide	  (LPS)	  from	  the	  cell	  wall	  of	  Gram-­‐negative	  bacteria,	  as	  well	  as	  endogenous	  signals	  such	  as	  HSP70,	  HSP90,	  and	  HMGB-­‐1.	  Agonism	  of	  the	  receptor	  is	  dependent	  upon	  the	  accessory	  protein	  MD2	  which	  is	  responsible	  for	  binding	  LPS	  and	  mediating	  the	  interaction	  between	  TLR4	  receptors	  in	  an	  active	  signaling	  unit.	  The	  recent	  crystal	  structures	  of	  the	  TLR4/MD2	  complex	  demonstrate	  that	  all	  of	  the	  critical	  residues	  for	  the	  MD2	  interaction	  with	  TLR4	  are	  localized	  to	  one	  stretch	  (C95-­‐E111)	  of	  MD2.	  Moreover,	  this	  stretch	  of	  amino	  acids	  is	  constrained	  by	  a	  crucial	  disulfide	  bond	  (C95-­‐C105).	  The	  proximity	  of	  these	  critical	  features	  suggests	  that	  an	  MD2	  based	  synthetic	  peptide	  incorporating	  these	  critical	  elements	  could	  compete	  with	  full-­‐length	  MD2	  for	  the	  TLR4	  binding	  interface	  and	  subsequently	  prevent	  signaling.	  	  This	  study	  investigates	  the	  feasibility	  of	  such	  an	  approach	  and	  demonstrates	  that	  a	  17	  residue	  peptide	  based	  on	  the	  TLR4	  binding	  region	  of	  MD2	  can	  prevent	  full-­‐length	  MD2	  from	  associating	  with	  TLR4	  and	  subsequently	  prevent	  TLR4	  signaling.	  	  Bacteria	  utilize	  large	  multi-­‐protein	  chemosensory	  arrays	  to	  sense	  attractants	  and	  repellants	  in	  their	  environment.	  	  The	  essential	  components	  of	  these	  arrays	  are	  hexagonally	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arranged	  core	  units	  consisting	  of	  receptor	  trimer-­‐of-­‐dimers,	  CheA	  histidine	  kinase,	  and	  CheW	  coupling	  protein.	  	  Incorporation	  of	  these	  units	  into	  arrays	  has	  several	  advantages	  including	  strong	  cooperativity	  and	  high	  sensitivity	  in	  ligand	  sensing,	  a	  large	  dynamic	  range	  and	  rapid	  signal	  transduction	  through	  the	  signalling	  circuit.	  	  Another	  unique	  advantage	  of	  the	  array	  architecture	  is	  a	  striking	  ultra-­‐stability	  in	  
vitro:	  arrays	  retain	  kinase	  activity,	  attractant	  sensitivity	  and	  bound	  components	  for	  weeks.	  This	  work	  examines	  this	  remarkable	  ultra-­‐stability	  and	  its	  origin	  in	  more	  detail.	  The	  results	  of	  this	  study	  demonstrate	  that	  arrays	  are	  not	  homogenous,	  but	  rather	  exhibit	  two	  major	  populations.	  One	  population	  is	  quasi-­‐stable	  with	  a	  lifetime	  of	  1-­‐2	  days,	  and	  loss	  of	  this	  population	  is	  highly	  correlated	  with	  proteolytic	  degradation	  of	  CheA	  kinase.	  The	  second	  population	  is	  truly	  ultra-­‐stable	  with	  a	  lifetime	  of	  20	  days	  or	  more,	  and	  is	  less	  accessible	  to	  proteolysis.	  Following	  degradation	  of	  the	  less	  stable	  population,	  the	  cooperativity	  of	  the	  array	  increases,	  arguing	  that	  the	  less	  stable	  regions	  of	  array	  are	  not	  as	  well	  ordered	  and	  cooperative	  as	  the	  ultra-­‐stable	  regions.	  To	  test	  the	  hypothesis	  that	  a	  well-­‐ordered	  array	  is	  required	  for	  ultra-­‐stability,	  we	  have	  introduced	  a	  small	  density	  of	  defects	  into	  the	  complex	  through	  chemical	  modification.	  	  Notably,	  even	  a	  very	  low	  degree	  of	  packing	  defects	  can	  abolish	  array	  ultra-­‐stability,	  supporting	  the	  hypothesis.	  These	  findings	  are	  consistent	  with	  a	  model	  in	  which	  cooperativity	  and	  ultra-­‐stability	  arise	  from	  extensive	  interconnectivity	  between	  multiple	  components	  within	  a	  well-­‐ordered	  array.	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Chapter	  1	  –	  Pathological	  Pain	  and	  the	  Role	  of	  TLR4	  
Pathological	  Pain.	  There	  are	  two	  common	  types	  of	  pain,	  acute	  and	  pathological.	  Acute	  pain	  is	  a	  healthy	  response	  that	  is	  adaptive	  and	  short	  lived.	  This	  type	  of	  pain	  helps	  prevent	  further	  injury	  to	  the	  organism	  and	  disappears	  once	  the	  damage	  or	  injury	  has	  been	  corrected.	  Pathological	  pain	  is	  a	  non-­‐healthy	  form	  of	  pain	  that	  is	  persistent	  and	  non-­‐adaptive	  and	  often	  spreads	  to	  nearby	  healthy	  tissues1.	  	  Pathological	  pain	  can	  be	  further	  divided	  into	  two	  subclasses:	  neuropathic	  pain	  and	  inflammatory	  pain.	  Neuropathic	  pain	  originates	  from	  damage	  to	  the	  peripheral	  nervous	  system	  (PNS)	  and	  central	  nervous	  system	  (CNS)	  while	  inflammatory	  pain	  originates	  from	  tissue	  damage	  or	  inflammation	  (scar	  tissue,	  arthritis,	  infection,	  etc.).	  Some	  characteristic	  symptoms	  of	  pathological	  pain	  are	  enhanced	  sensitivity	  to	  noxious	  stimuli	  (hyperalgesia),	  painful	  responses	  to	  innocuous	  stimuli	  (allodynia),	  and	  spontaneous	  pain2-­‐6.	  	  Pathological	  pain	  states	  are	  thought	  to	  arise	  from	  sensitization	  of	  both	  nociceptive	  primary	  afferent	  neurons	  in	  the	  PNS	  and	  hyperexcitability	  of	  nociceptive	  neurons	  in	  the	  CNS7.	  
The	  Role	  of	  Glial	  Cells	  in	  Pathological	  Pain.	  Glial	  cells	  are	  the	  immune	  system’s	  first	  line	  of	  defense	  in	  the	  CNS	  and	  constitute	  more	  than	  70%	  of	  the	  total	  number	  of	  cells	  in	  the	  brain	  and	  spinal	  cord8.	  The	  three	  major	  types	  of	  glial	  cells	  are	  microglia,	  oligodendrocytes,	  and	  astrocytes.	  These	  cells	  are	  highly	  similar	  to	  macrophages	  and	  play	  a	  significant	  role	  in	  fighting	  off	  infection	  and	  responding	  to	  injury	  in	  the	  CNS9,	  10.	  In	  response	  to	  injury,	  these	  cells	  release	  a	  variety	  of	  pro-­‐inflammatory	  molecules	  including	  nitric	  oxide	  (NO),	  interleukin	  1β	  (IL-­‐1β),	  interleukin	  6	  (IL-­‐6),	  tumor	  necrosis	  factor	  α	  (TNFα),	  and	  many	  others.	  These	  pro-­‐inflammatory	  molecules	  direct	  a	  robust	  immune	  response	  that	  fights	  infection,	  clears	  cellular	  debris,	  and	  repairs	  damaged	  tissues11.	  Unfortunately,	  these	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molecules	  also	  stimulate	  a	  variety	  of	  neuronal	  signaling	  pathways	  that	  increase	  the	  excitability	  of	  neurons	  (Figure	  1.1).	  Specifically,	  these	  pro-­‐inflammatory	  mediators	  direct	  the	  down	  regulation	  of	  excitatory	  amino	  acid	  transporters	  such	  as	  glutamate	  transporter	  1	  and	  glutamate-­‐aspartate	  transporter,	  causing	  decreased	  glutamate	  uptake	  and	  increased	  excitatory	  transmission12,	  13.	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Toll-­like	  Receptors,	  Glial	  Cell	  Activation,	  and	  Pathological	  Pain.	  Toll-­‐like	  receptors	  (TLRs)	  are	  a	  family	  of	  receptors	  in	  the	  innate	  immune	  system.	  These	  receptors	  are	  activated	  by	  recognition	  of	  structural	  patterns	  that	  are	  common	  to	  bacteria	  and	  viruses	  known	  as	  pathogen	  associated	  molecular	  patterns	  or	  PAMPs.	  Some	  of	  these	  structures	  include	  lipopolysaccharide,	  lipoproteins,	  lipopeptides,	  flagellin,	  double	  stranded	  RNA,	  and	  unmethylated	  islands	  of	  CG	  rich	  DNA.	  In	  addition	  to	  pathogenic	  signals,	  TLRs	  also	  recognize	  endogenous	  danger	  signals	  referred	  to	  as	  damage	  associated	  molecular	  patterns	  (DAMPs).	  DAMPs	  can	  be	  full-­‐length	  proteins	  such	  as	  Hsp70,	  Hsp90,	  and	  HMGB-­‐1	  or	  simply	  cellular	  debris15.	  Regardless	  of	  the	  origin,	  agonism	  of	  TLRs	  leads	  to	  the	  activation	  of	  NF-­‐κB	  and	  AP-­‐1	  transcription	  factors16,	  17.	  These	  transcription	  factors	  initiate	  the	  production	  of	  many	  of	  the	  aforementioned	  pro-­‐inflammatory	  cytokines	  (IL-­‐1β,	  IL-­‐6,	  TNFα,	  etc.)	  that	  are	  documented	  in	  the	  pathological	  pain.	  TLRs	  are	  robustly	  expressed	  on	  all	  types	  of	  glial	  cells18.	  The	  first	  direct	  evidence	  that	  TLRs	  contribute	  to	  pathological	  pain	  was	  established	  by	  demonstrating	  that	  infection	  or	  pseudo-­‐infection	  with	  bacterial	  components	  leads	  to	  pathological	  pain	  states19.	  More	  recently	  it	  has	  been	  demonstrated	  that	  suppression	  or	  knockout	  of	  TLRs	  can	  reverse	  or	  prevent	  the	  progression	  of	  pathological	  pain	  states19.	  
TLR	  Structure,	  Activation,	  and	  Signal	  Transduction.	  TLRs	  are	  horseshoe-­‐shaped	  transmembrane	  receptors	  consisting	  primarily	  of	  leucine	  rich	  repeats	  (LRRs).	  The	  extracellular	  horseshoe	  is	  coupled	  to	  a	  single	  transmembrane	  domain	  and	  an	  intracellular	  toll/interlekin-­‐1	  receptor	  (TIR)	  domain15.	  Activation	  of	  TLRs	  begins	  with	  homo-­‐	  or	  hetero-­‐dimerization	  of	  two	  TLR	  monomers.	  Among	  the	  TLRs,	  TLR3,	  TLR4,	  TLR5,	  TLR7,	  TLR8,	  and	  TLR9	  are	  known	  to	  form	  homodimers	  and	  TLR2/1	  and	  TLR2/6	  are	  known	  to	  form	  hetero-­‐dimers.	  TLRs	  are	  believed	  to	  form	  weak	  dimers	  in	  the	  absence	  of	  ligand.	  However,	  in	  the	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presense	  of	  ligand,	  these	  receptors	  form	  tight	  dimers	  extracellularly	  and	  propagate	  the	  structural	  change	  to	  the	  cytosolic	  TIR	  domains	  which	  also	  form	  tight	  dimers.	  Dimerization	  of	  the	  TIR	  domains	  creates	  a	  platform	  for	  signal	  transduction	  (Figure	  1.2).	  	  
	  	  
Figure	  1.2:	  Structural	  model	  of	  TLR	  activation.	  TLRs	  form	  weak	  dimers	  through	  interactions	  in	  the	  extracellular	  LRR	  structures.	  In	  the	  weak	  dimer,	  intracellular	  TIR	  domains	  are	  not	  strongly	  associated	  and	  do	  not	  recruit	  signaling	  adaptors.	  Ligand	  binding	  to	  the	  extracellular	  dimer	  (lipoprotein	  is	  shown	  here)	  causes	  TLRs	  to	  form	  a	  tight	  dimer.	  Subsequently,	  TIR	  domains	  also	  strongly	  associate	  creating	  a	  platform	  for	  the	  recruitment	  of	  signaling	  proteins.	  Some	  TLRs	  are	  believed	  to	  have	  significant	  interactions	  in	  the	  transmembrane	  (TM)	  domain	  that	  help	  drive	  dimerization	  and	  rearrangement	  of	  the	  TIR	  domains15.	  Crystal	  structures	  shown	  here	  are:	  TIR	  domain,	  2J67	  and	  TLR1/2,	  2Z7X.	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The	  targets	  for	  these	  platforms	  include	  MyD88,	  Mal,	  TRIF,	  TRAM,	  and	  SARM.	  MyD88	  and	  Mal	  specifically	  initiate	  NF-­‐κB	  signaling,	  while	  TRIF	  and	  TRAM	  initiate	  IRF1,	  IRF3,	  IRF5,	  and	  IRF7	  signaling.	  SARM	  serves	  as	  a	  repressor	  of	  these	  pathways18.	  	  
The	  Unique	  Case	  of	  Toll-­like	  Receptor	  4.	  TLR4	  represents	  one	  of	  the	  best	  studied	  members	  of	  the	  toll-­‐like	  receptor	  family.	  First	  identified	  in	  1998	  by	  Poltorak	  et	  al.	  as	  the	  cellular	  response	  protein	  to	  lipopolysaccharide	  (LPS),	  TLR4	  has	  since	  become	  associated	  with	  a	  number	  of	  immune-­‐related	  disease	  states	  including	  diabetes,	  cancers,	  and	  the	  aforementioned	  pathological	  pain8,	  20-­‐22.	  TLR4	  is	  unique	  among	  toll-­‐like	  receptors	  in	  its	  ability	  to	  induce	  both	  MyD88-­‐dependent	  signaling	  cascades	  and	  TRIF-­‐dependent	  signaling	  cascades	  depending	  on	  its	  cellular	  localization23.	  	  TLR4	  is	  the	  only	  TLR	  that	  is	  known	  to	  interact	  with	  all	  four	  of	  the	  known	  TIR-­‐domain	  containing	  adaptors	  (MyD88,	  Mal,	  TRIF,	  and	  TRAM)	  and	  may	  interact	  with	  a	  fifth	  adaptor	  (SARM)18.	  Finally,	  TLR4	  is	  unique	  in	  that	  it	  requires	  a	  soluble	  accessory	  protein	  (MD2)	  to	  help	  recognize	  its	  pathogenic	  ligand	  and	  mediate	  dimerization.	  	  Most	  importantly,	  downregulation	  of	  TLR4	  by	  an	  antisense	  oligonucleotide	  or	  knockout	  of	  the	  receptor	  has	  been	  shown	  to	  reduce	  glial	  activation	  and	  prevent	  the	  development	  of	  pathological	  pain24.	  	  
LPS	  Recognition	  by	  TLR4.	  Activation	  of	  TLR4	  is	  caused	  by	  the	  endotoxin	  LPS	  from	  the	  cell	  wall	  of	  Gram	  negative	  bacteria.	  LPS	  does	  not	  exist	  as	  a	  monomer	  in	  solution	  but	  rather	  forms	  aggregates	  that	  must	  be	  disassembled	  before	  recognition	  can	  occur.	  This	  process	  is	  accomplished	  by	  a	  variety	  of	  blood	  serum	  proteins	  and	  one	  LPS	  specific	  protein	  known	  as	  LPS-­‐binding	  protein	  (LBP).	  LBP	  is	  small	  globular	  protein	  that	  binds	  LPS	  and	  removes	  it	  from	  aggregates.	  The	  LBP-­‐LPS	  complex	  binds	  to	  a	  cell	  surface	  receptor,	  CD14	  and	  LPS	  is	  subsequently	  transferred	  to	  this	  receptor25,	  26.	  Finally,	  LPS	  can	  be	  transferred	  from	  CD14	  to	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MD2—a	  small	  beta-­‐barrel	  protein	  that	  forms	  a	  stable	  interaction	  with	  TLR427.	  The	  TLR4/MD2/LPS	  complex	  subsequently	  binds	  very	  tightly	  to	  another	  TLR4/MD2/LPS	  complex	  initiating	  the	  TIR	  dimer	  formation	  that	  is	  required	  for	  signaling	  (Figure	  1.3)28.	  	  	  
Figure	  1.3:	  Activation	  of	  the	  TLR4/MD2	  complex	  by	  LPS.	  From	  top	  left,	  LPS	  dissociates	  from	  the	  cell	  wall	  of	  Gram	  negative	  bacteria	  and	  forms	  aggregates	  in	  solution.	  LPS	  is	  removed	  from	  aggregates	  by	  LBP.	  LBP-­‐LPS	  complexes	  bind	  to	  CD14	  and	  the	  LPS	  molecule	  is	  transferred	  to	  the	  surface	  receptor.	  CD14-­‐LPS	  complexes	  interact	  with	  TLR4-­‐MD2	  complexes	  on	  the	  cell	  surface	  and	  LPS	  is	  transferred	  to	  MD2.	  TLR4/MD2/LPS	  complexes	  form	  tightly	  coupled	  active	  signaling	  dimers	  with	  other	  complexes29.	  Crystal	  structures	  shown	  here	  are:	  TIR	  domain,	  2J67	  and	  TLR4/MD2,	  3FXI.	  	  
The	  TLR4/MD2	  Complex.	  At	  the	  heart	  of	  LPS	  recognition	  is	  the	  TLR4/MD2	  complex.	  The	  presence	  of	  this	  complex	  is	  absolutely	  required	  for	  LPS	  recognition	  as	  the	  absence	  of	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either	  protein	  abolishes	  LPS	  responses20,	  30,	  31.	  Moreover,	  even	  small	  perturbations	  at	  the	  TLR4/MD2	  interface	  lead	  to	  reduced	  cellular	  responses	  and	  altered	  cellular	  trafficking	  of	  TLR430,	  32.	  The	  interface	  between	  these	  two	  proteins	  is	  long	  and	  narrow	  comprising	  about	  800	  Å2	  of	  surface	  area29.	  In	  addition	  to	  the	  buried	  surface	  area,	  a	  number	  of	  charged	  interactions	  are	  present	  along	  this	  interface	  (Figure	  1.4).	  TLR4	  has	  two	  oppositely	  charged	  patches	  along	  this	  interface,	  one	  negatively	  charged	  patch	  comprised	  of	  E41,	  D83,	  E134	  and	  one	  positively	  charged	  patch	  comprised	  of	  R233,	  R263,	  R288	  (Figure	  1.4	  A	  and	  B).	  These	  patches	  interact	  with	  oppositely	  charged	  patches	  on	  MD2	  comprised	  of	  R68,	  K109,	  R106	  and	  D99,	  D100,	  D101,	  E111	  (Figure	  1.4	  C	  and	  D)29,	  33.	  There	  are	  also	  significant	  hydrophobic	  and	  hydrogen	  bonding	  interactions	  at	  this	  interface.	  Studies	  of	  MD2	  have	  revealed	  that	  positions	  Y102	  and	  S103	  are	  critical	  for	  MD2	  binding	  and	  activity32.	  One	  more	  feature	  of	  this	  interface	  is	  the	  requirement	  of	  a	  structurally	  constraining	  disulfide	  bond	  on	  MD2	  (C95-­‐C105,	  Figure	  1.4D)32,	  34.	  This	  disulfide	  is	  believed	  to	  helps	  to	  reduce	  the	  entropic	  penalty	  associated	  with	  binding	  by	  reducing	  flexibility	  in	  the	  TLR4	  interacting	  region	  of	  MD2.	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Figure	  1.4:	  Electrostatic	  interactions	  between	  TLR4	  and	  MD2.	  A,	  TLR4	  has	  two	  patches	  that	  cluster	  positive	  charges	  and	  negative	  charges.	  B,	  Close	  up	  of	  critical	  charged	  residues	  in	  the	  MD2	  binding	  region	  of	  TLR4.	  Critical	  residues	  are	  highlighted	  as	  sticks	  with	  negatively	  charged	  residues	  in	  red	  and	  positively	  charged	  residues	  in	  blue.	  C,	  Interaction	  between	  TLR4	  and	  MD2.	  D,	  Close	  up	  of	  critical	  charged	  residues	  on	  MD2	  and	  their	  partners	  on	  TLR4.	  Critical	  residues	  are	  highlighted	  as	  sticks.	  The	  disulfide	  bond	  that	  constrains	  the	  MD2	  binding	  region	  is	  shown	  in	  yellow.	  	  
Inhibition	  of	  TLR4	  Initiated	  Signaling.	  The	  diverse	  role	  of	  TLR4	  in	  a	  number	  of	  disease	  states	  has	  created	  a	  need	  for	  transient,	  reversible	  inhibitors	  of	  the	  receptor.	  Early	  efforts	  to	  inhibit	  TLR4	  signaling	  focused	  on	  analogs	  of	  LPS	  that	  bind	  MD2	  but	  do	  not	  induce	  tight	  dimerization	  of	  receptors.	  These	  alter	  the	  number	  and	  length	  of	  the	  lipid	  chains	  on	  
	   9	  
LPS,	  and	  also	  remove	  one	  or	  both	  of	  its	  phosphate	  groups.	  Two	  noteworthy	  inhibitors	  to	  come	  out	  of	  this	  class	  were	  E5564	  (Eritoran)	  and	  Lipid	  A	  from	  Rhodobacter	  capsulatus35,	  36.	  Unfortunately,	  these	  inhibitors	  require	  very	  large	  doses	  (>	  1	  mg/mL)	  and	  suffer	  from	  poor	  efficacy	  in	  vivo37.	  An	  additional	  inhibitor	  is	  a	  TLR4/MD2	  fusion	  protein	  that	  binds	  LPS	  and	  sequesters	  the	  molecule	  in	  solution38.	  	  A	  more	  tractable	  solution	  to	  the	  problem	  has	  come	  in	  the	  form	  of	  small	  molecules	  and	  peptides.	  One	  success	  story	  in	  the	  field	  of	  small	  molecules	  is	  TAK-­‐242	  which	  targets	  the	  TIR	  domain	  of	  TLR4	  and	  prevents	  it	  from	  dimerizing39.	  Another	  small	  molecule	  (2126)	  has	  been	  discovered	  that	  reportedly	  prevents	  MD2	  from	  binding	  to	  TLR4—although	  the	  molecule’s	  mode	  of	  action	  has	  not	  been	  experimentally	  verified40,	  41.	  Peptides	  have	  proven	  quite	  effective	  at	  preventing	  TLR4	  signaling.	  Peptides	  derived	  from	  MD2	  and	  TLR4	  have	  been	  shown	  to	  prevent	  TLR4	  signaling	  through	  a	  variety	  of	  modes	  of	  actions	  including	  binding	  LPS42,	  blocking	  TLR4	  dimerization43,	  and	  preventing	  TIR	  interactions	  with	  MyD8844.	  	  
Targeting	  the	  TLR4/MD2	  Interface.	  Preventing	  MD2	  from	  associating	  with	  TLR4	  is	  a	  tantalizing	  target	  for	  the	  development	  of	  peptide	  or	  small	  molecule	  inhibitors.	  Blocking	  this	  interface	  does	  not	  involve	  competitive	  inhibition	  of	  LPS	  which	  binds	  MD2	  very	  tightly	  (3-­‐65	  nM)	  and	  has	  a	  very	  slow	  off	  rate	  (1-­‐2	  hours)27.	  Blocking	  the	  interface	  could	  also	  disrupt	  cellular	  trafficking	  of	  TLR4—which	  requires	  MD2	  to	  be	  trafficked	  to	  the	  cell	  surface31.	  	  The	  TLR4	  binding	  pocket	  on	  MD2	  provides	  a	  good	  structural	  starting	  point	  for	  the	  design	  of	  such	  an	  inhibitor.	  The	  charged	  and	  hydrogen	  bonding	  residues	  on	  MD2	  that	  are	  critical	  for	  TLR4	  binding	  are	  all	  located	  in	  one	  short	  stretch	  of	  the	  protein	  (C95RGSDDDYSFCRALKGE111)33.	  This	  sequence	  also	  contains	  the	  constraining	  disulfide	  bond	  that	  is	  critical	  for	  MD2	  binding	  to	  TLR4.	  The	  presence	  of	  all	  of	  these	  critical	  features	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suggests	  that	  the	  peptide	  sequence	  may	  bind	  TLR4	  without	  the	  remainder	  of	  the	  MD2	  structure32.	  Moreover,	  since	  this	  short	  MD2	  sequence	  does	  not	  contain	  any	  of	  the	  LPS	  binding	  elements	  of	  MD2,	  the	  peptide	  should	  not	  bind	  LPS	  or	  help	  mediate	  the	  formation	  of	  the	  TLR4	  signaling	  complex.	  	  
Figure	  1.5:	  Interaction	  of	  the	  C95-­‐E111	  MD2	  peptide	  with	  TLR4.	  TLR4	  is	  shown	  in	  green	  and	  the	  peptide	  is	  shown	  in	  blue.	  Critical	  residues	  for	  both	  binding	  partners	  are	  shown	  as	  sticks	  and	  the	  constraining	  disulfide	  is	  shown	  in	  orange.	  The	  proposed	  MD2	  peptide	  retains	  all	  of	  the	  critical	  residues	  for	  MD2	  binding	  but	  lacks	  the	  LPS	  binding	  beta-­‐barrel.	  	  	   Chapter	  2	  begins	  with	  a	  study	  that	  attempts	  to	  utilize	  this	  17-­‐residue,	  C95-­‐E111	  peptide	  to	  block	  TLR4	  signaling	  in	  a	  variety	  of	  cell	  based	  assays.	  The	  study	  attempts	  to	  show	  that	  the	  peptides	  is	  specific	  for	  TLR4	  among	  other	  toll-­‐like	  receptors,	  and	  finishes	  by	  characterizing	  the	  mode	  of	  action	  for	  the	  peptide.	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Chapter	  2	  -­	  A	  Constrained	  Peptide	  that	  Targets	  the	  TLR4/MD2	  Interaction	  	  
Abstract	  	   Pathologcial	  pain	  is	  a	  serious	  health	  problem	  that	  is	  initiated	  and	  perpetuated	  by	  TLRs	  on	  glial	  cells.	  Among	  the	  TLRs,	  TLR4	  is	  one	  of	  most	  studied	  and	  most	  significant	  members	  of	  the	  TLR	  family	  that	  organizes	  an	  innate	  immune	  response	  and	  distinguishes	  exogenous	  and	  endogenous	  danger	  signals45.	  Specifically,	  TLR4	  recognizes	  LPS	  from	  the	  cell	  wall	  of	  Gram-­‐negative	  bacteria,	  as	  well	  as	  endogenous	  signals	  such	  as	  HSP70,	  HSP90,	  and	  HMGB-­‐114.	  Agonism	  of	  the	  receptor	  is	  dependent	  upon	  the	  accessory	  protein	  MD2	  which	  is	  responsible	  for	  binding	  LPS	  and	  mediating	  the	  interaction	  between	  TLR4	  receptors	  in	  an	  active	  signaling	  unit46.	  The	  recent	  crystal	  structures	  of	  the	  TLR4/MD2	  complex	  demonstrate	  that	  all	  of	  the	  critical	  residues	  for	  the	  MD2	  interaction	  with	  TLR4	  are	  localized	  to	  one	  stretch	  (C95-­‐E111)	  of	  MD2.	  Moreover,	  this	  stretch	  of	  amino	  acids	  is	  constrained	  by	  a	  crucial	  disulfide	  bond	  (C95-­‐C105)28,	  33.	  The	  proximity	  of	  these	  critical	  features	  suggests	  that	  an	  MD2	  based	  synthetic	  peptide	  incorporating	  these	  critical	  elements	  could	  compete	  with	  full-­‐length	  MD2	  for	  the	  TLR4	  binding	  interface	  and	  subsequently	  prevent	  signaling.	  	  This	  study	  investigates	  the	  feasibility	  of	  such	  an	  approach	  and	  demonstrates	  that	  a	  17	  residue	  peptide	  based	  on	  the	  TLR4	  binding	  region	  of	  MD2	  can	  prevent	  full-­‐length	  MD2	  from	  associating	  with	  TLR4	  and	  subsequently	  prevent	  TLR4	  signaling.	  	  
Introduction	  	   Pathological	  pain	  occurs	  in	  epidemic	  proportions	  worldwide1.	  The	  disease	  typically	  arises	  from	  two	  types	  of	  injuries:	  1)	  tissue	  injuries	  that	  lead	  to	  inflammatory	  pain,	  and	  2)	  nerve	  injuries	  that	  lead	  to	  neuropathic	  pain.	  Glial	  cells	  in	  the	  CNS	  recognize	  a	  variety	  of	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signals	  associated	  with	  inflammatory	  or	  nerve	  injury	  and	  subsequently	  release	  a	  variety	  of	  inflammatory	  mediators	  in	  response,	  including	  TNFα,	  IL-­‐1β,	  IL-­‐6,	  PGE-­‐2,	  COX-­‐2,	  and	  ATP.	  The	  release	  of	  these	  molecules	  stimulates	  other	  glia	  to	  release	  pro-­‐inflammatory	  molecules,	  and	  also	  results	  in	  neuronal	  actions.	  Stimulation	  of	  nociceptive	  pain	  neurons	  by	  glial	  inflammatory	  mediators	  leads	  to	  hypersensitivity	  and	  enhanced	  pain	  states.	  The	  hypersensitive	  state	  leads	  to	  intense	  and	  exaggerated	  pain1,	  14.	  Previous	  research	  has	  indicated	  that	  TLR4	  plays	  a	  major	  role	  in	  the	  development	  of	  pathological	  pain47-­‐49.	  TLR4	  is	  well	  documented	  to	  become	  activated	  by	  so-­‐called	  endogenous	  danger	  signals.	  Moreover,	  TLR4-­‐knockout	  mice	  that	  have	  undergone	  nerve	  injury	  do	  not	  develop	  pathological	  pain	  and	  show	  reduced	  glial	  activation	  with	  lower	  levels	  of	  pro-­‐inflammatory	  molecules24.	  Hypersensitivity	  can	  be	  attenuated	  in	  pathological	  pain	  rats	  by	  using	  a	  TLR4	  antisense	  oligonucleotide24.	  TLR4	  signaling	  is	  dependent	  upon	  the	  formation	  of	  a	  homo-­‐dimer,	  which	  is	  mediated	  by	  the	  accessory	  protein	  MD250,	  51.	  Specific	  point	  mutations	  to	  MD2	  (for	  example,	  Cys95Tyr),	  which	  prevent	  its	  association	  with	  TLR4,	  significantly	  diminishes	  TLR4	  signaling52.	  TLR4-­‐based	  peptides	  or	  TLR4-­‐MD2	  fusion	  proteins	  can	  also	  attenuate	  signaling	  by	  competing	  for	  MD2	  or	  LPS	  respectively38,	  53.	  Given	  the	  wide	  array	  of	  agonists	  that	  TLR4	  recognizes,	  it	  is	  not	  clear	  whether	  a	  peptide	  that	  targets	  TLR4	  directly	  would	  agonize	  or	  antagonize	  the	  receptor.	  The	  recently	  reported	  high-­‐resolution	  crystal	  structure	  of	  the	  TLR4–MD2	  complex	  revealed	  several	  molecular	  recognition	  sites	  on	  the	  TLR4–MD2	  interface	  that	  could	  serve	  as	  potential	  targets	  for	  a	  peptide33.	  A	  charged	  patch	  spanning	  from	  Asp99	  to	  Glu111	  of	  MD2	  was	  projected	  to	  be	  critical	  to	  the	  nanomolar	  binding	  affinity	  of	  MD2	  and	  TLR4.	  These	  charged	  residues	  are	  projected	  by	  a	  short	  α	  helix	  (Ser103–
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Lys109)	  and	  a	  random-­‐coil	  protruding	  loop	  (Cys95–Tyr102)	  that	  is	  constrained	  by	  a	  disulfide	  bridge	  between	  Cys95	  and	  Cys10532.	  Herein,	  we	  employ	  a	  chemical	  biology	  approach	  by	  utilizing	  the	  minimal	  TLR4-­‐binding	  region	  of	  MD2	  to	  block	  the	  TLR4–MD2	  association	  (Figure	  2.1).	  
Figure	  2.1:	  Preventing	  TLR4	  signaling	  with	  a	  C95-­‐E111	  MD2	  based	  peptide.	  TLR4/MD2	  dimers	  are	  delivered	  to	  the	  cell	  membrane	  where	  MD2	  binds	  the	  endotoxin	  LPS.	  LPS	  binding	  triggers	  the	  formation	  of	  a	  tetrameric	  signaling	  complex	  with	  two	  TLR4	  and	  two	  MD2	  molecules.	  MD2-­‐I	  competes	  for	  the	  MD2	  binding	  site	  on	  TLR4.	  In	  the	  absence	  of	  MD2,	  LPS	  cannot	  bind	  and	  trigger	  the	  formation	  of	  the	  tetramer.	  Crystal	  structures	  for	  TLR4	  and	  MD2	  are	  modified	  from	  PDB,	  3FXI.	  	   The	  in	  vitro	  and	  whole-­‐cell	  data	  presented	  here	  demonstrate	  for	  the	  first	  time	  that	  an	  MD2-­‐based	  peptide	  inhibitor	  can	  suppress	  TLR4	  signaling.	  Moreover,	  the	  peptide	  is	  also	  highly	  specific	  for	  TLR4	  and	  suppresses	  signaling	  by	  direct	  competition	  for	  the	  MD2	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binding	  site	  on	  TLR4.	  This	  study	  introduces	  a	  novel	  strategy	  for	  antagonizing	  TLR4	  and	  may	  lead	  to	  novel	  treatments	  for	  CNS	  disorders.	  
Materials	  and	  Methods	  
Materials.	  Chemical	  reagents	  were	  obtained	  from	  Sigma	  Aldrich	  with	  the	  following	  exceptions:	  HBTU,	  HOBt,	  and	  FMOC-­‐amino	  acids	  were	  obtained	  from	  ChemPep,	  ultra-­‐pure	  TLR	  ligands	  (LPS,	  ssDNA,	  pam3CSK4,	  peptidoglycan,	  ssDNA,	  poly(I:C))	  were	  obtained	  from	  Invivogen,	  CSPD	  luminescence	  detection	  kit	  was	  obtained	  from	  Applied	  Biosystems,	  and	  cell	  culture	  reagents	  (DMEM,	  FBS,	  etc.)	  were	  obtained	  from	  Gibco.	  Any	  other	  exceptions	  are	  noted	  in	  the	  methods.	  Cell	  lines	  were	  obtained	  from	  ATCC	  unless	  otherwise	  noted.	  	  
Peptide	  Synthesis	  and	  Purification.	  All	  peptides	  were	  synthesized	  in	  the	  CEM	  Discover	  microwave	  by	  using	  the	  standard	  FMOC	  chemistry	  that	  was	  outlined	  by	  Bacsa	  and	  Kappe	  with	  modifications54.	  Five	  equivalents	  of	  HBTU:HOBt	  (1:1)	  coupling	  reagent	  and	  five	  equivalents	  of	  amino	  acid	  were	  used	  per	  coupling.	  Each	  coupling	  was	  performed	  once	  except	  for	  arginine	  and	  cysteine	  residues	  which	  were	  performed	  twice.	  Coupling	  times	  and	  microwave	  intensity	  were	  adjusted	  according	  to	  specifications	  from	  CEM.	  After	  cleavage	  and	  workup,	  peptides	  were	  characterized	  by	  using	  Perseptive	  Biosystems	  MALDI-­‐TOF	  Mass	  Spectrometer.	  Purification	  of	  peptides	  was	  carried	  out	  on	  a	  Waters	  600E	  HPLC	  equipped	  with	  a	  Sepax	  GP-­‐C8	  reversed-­‐phase,	  21.2x250	  mm	  column	  over	  a	  90:10	  to	  70:30	  (H2O,	  0.1%	  TFA:acetonitrile,	  0.1%	  TFA)	  gradient	  for	  30	  min.	  Fractions	  containing	  purified	  peptide	  were	  lyophilized	  to	  dryness	  and	  stored	  at	  -­‐80	  °C	  until	  use.	  
Flow	  Cytometry.	  Cells	  were	  lifted	  on	  the	  day	  of	  experiment	  and	  centrifuged	  at	  1000	  rpm	  for	  5	  min.	  Medium	  was	  decanted	  and	  replaced	  with	  cerebral	  spinal	  fluid	  (CSF)	  buffer	  (124	  mM	  NaCl,	  5	  mM	  KCl,	  0.1	  mM	  CaCl2,	  3.2	  mM	  MgCl2,	  26	  mM	  NaHCO3,	  and	  10	  mM	  glucose,	  
	   15	  
pH	  7.4)	  to	  a	  final	  concentration	  of	  1x106	  cells/mL.	  Cells	  were	  aliquoted	  (800	  μL	  per	  tube)	  into	  5	  mL	  sorter	  tubes	  and	  coincubated	  with	  100	  ng/mL	  LPS-­‐FITC	  (100	  μL)	  and	  H2O	  (100	  μL)	  or	  a	  peptide	  solution	  (100	  μL).	  After	  2	  h,	  cells	  were	  counted	  using	  a	  MoFlo	  DakoCytomation	  cell	  sorter	  that	  was	  equipped	  with	  a	  488	  nm	  argon	  laser.	  Summit	  Software	  v4.0	  was	  used	  to	  collect	  and	  quantify	  the	  data.	  A	  total	  of	  ten	  thousand	  events	  were	  collected	  for	  each	  sample	  
Luminescence	  (SEAP)	  Assay.	  Human	  embryonic	  kidney	  293	  (HEK293)	  cells	  that	  were	  stably	  transfected	  with	  TLR4/MD2	  and	  a	  secreted	  alkaline	  phosphatase	  (SEAP)	  reporter	  gene	  were	  obtained	  from	  InvivoGen.	  Cells	  were	  cultured	  in	  DMEM	  supplemented	  with	  10%	  FBS,	  penicillin	  (100	  U/mL),	  streptomycin	  (100	  μg/mL),	  L-­‐glutamine	  (2	  mM),	  1x	  Normocin	  (InvivoGen)	  and	  2x	  HEK	  Blue	  Selection	  (InvivoGen)	  at	  37°C	  with	  5%	  CO2.	  Cells	  were	  implanted	  in	  96-­‐well	  plates	  24	  hours	  prior	  to	  drug	  treatment	  and	  incubated	  at	  37°C.	  On	  the	  day	  of	  treatment,	  media	  was	  removed	  from	  the	  96-­‐well	  plate	  and	  replaced	  with	  CSF	  buffer	  that	  contained	  a	  mixture	  of	  LPS	  and	  peptide.	  After	  24	  hours,	  a	  sample	  of	  CSF	  buffer	  (15	  μL)	  from	  each	  well	  was	  collected	  and	  transferred	  to	  an	  opaque	  white	  96-­‐well	  plate	  (Thermo	  Scientific).	  Levels	  of	  SEAP	  were	  detected	  using	  Applied	  Biosystems	  CSPD	  luminescence	  detection	  kit	  according	  to	  the	  manufacturer’s	  instructions	  and	  a	  Beckman	  Coulter,	  DTX	  880	  plate	  reader	  with	  Multimode	  Analysis	  Software.	  Raw	  luminescence	  scores	  were	  expressed	  as	  a	  percentage	  of	  luminescence	  against	  a	  control	  that	  contained	  only	  peptide.	  Each	  data	  point	  shown	  represents	  an	  average	  of	  three	  replicates	  and	  error	  bars	  show	  the	  standard	  deviation.	  
Murine	  Macrophage	  Akt1-­GFP	  Imaging.	  LPS-­‐induced	  activation	  of	  Akt1-­‐GFP	  was	  studied	  in	  RAW264.7	  mouse	  macrophages.	  These	  cells	  were	  stably	  transfected	  to	  express	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GFP-­‐tagged	  Akt1	  and	  graciously	  provided	  by	  Dr.	  J.	  Evans55.	  Cells	  were	  cultured	  in	  DMEM	  that	  was	  supplemented	  with	  10%	  FBS,	  penicillin	  (100	  U/mL),	  streptomycin	  (100	  μg/mL),	  L-­‐glutamine	  (2	  mM),	  and	  HEPES	  (20	  mM,	  pH	  7.5)	  in	  5%	  CO2	  at	  37°C	  and	  plated	  at	  2x105	  cells/mL	  24	  hours	  prior	  to	  imaging	  on	  3.5	  cm	  MatTek	  glass-­‐bottomed	  dishes.	  At	  the	  time	  of	  experiment,	  media	  was	  removed	  and	  cells	  were	  washed	  twice	  with	  Hank’s	  Balanced	  Salt	  Solution	  (HBSS)	  that	  was	  supplemented	  with	  25	  mM	  HEPES	  buffered	  to	  pH	  7.5.	  Conditioned	  HBSS	  (1.0	  mL)	  was	  added	  to	  the	  cells	  for	  imaging.	  HBSS	  was	  conditioned	  by	  a	  24	  hour	  incubation	  with	  RAW264.7	  cells.	  A	  Nikon	  inverted	  microscope	  with	  60x	  oil	  immersion	  objective,	  GFP/RFP	  dichroic	  mirror,	  corresponding	  single-­‐band	  excitation	  and	  emission	  filters,	  and	  CoolSNAP	  ES	  camera	  was	  used	  to	  carry	  out	  imaging.	  Excitation	  was	  provided	  with	  a	  mercury	  lamp.	  Images	  were	  taken	  every	  7.5	  s.	  Background	  fluorescence	  was	  captured	  for	  five	  frames.	  Peptides	  were	  added	  in	  a	  200	  μL	  dose	  to	  a	  final	  concentration	  of	  100	  μM.	  Twenty	  more	  frames	  were	  collected	  before	  200	  μL	  of	  LPS	  (200	  ng/mL	  final)	  was	  added.	  If	  no	  visual	  response	  occurred	  after	  twenty	  frames,	  C5a	  (25	  ng/mL	  final)	  was	  added	  to	  the	  plates	  to	  confirm	  if	  the	  cells	  were	  responsive.	  Translocation	  of	  Akt1-­‐GFP	  was	  quantified	  by	  using	  ImageJ	  and	  expressed	  as	  normalized	  change	  in	  cytoplasmic	  fluorescence	  (arbitrary	  units)	  over	  time.	  Each	  data	  point	  represent	  an	  average	  of	  9	  cells	  and	  error	  bars	  indicate	  the	  standard	  error	  in	  the	  measurement.	  
Nitrite	  Assay.	  RAW	  264.7	  cells	  were	  obtained	  from	  the	  ATCC	  and	  maintained	  in	  DMEM	  media	  supplemented	  with	  10%	  FBS,	  penicillin	  (100	  U/mL),	  streptomycin	  (100	  μg/mL),	  and	  glutamine	  (2	  mM)	  with	  5%	  CO2	  at	  37°C.	  On	  the	  day	  of	  experiment	  cells	  were	  lifted	  by	  mechanical	  shear,	  washed	  in	  Phosphate	  Buffered	  Saline	  (PBS),	  and	  resuspended	  in	  fresh	  media	  at	  a	  density	  of	  5	  x	  105	  cells/mL.	  Exactly	  200	  µL	  of	  cells	  were	  added	  to	  each	  well	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of	  a	  96	  well	  plate	  and	  allowed	  to	  recover	  overnight.	  Once	  recovered,	  media	  was	  removed	  and	  replaced	  with	  fresh	  media	  containing	  TLR	  ligand	  and	  the	  peptide	  to	  be	  tested.	  Plates	  were	  incubated	  overnight	  to	  allow	  detectable	  nitrite	  levels	  to	  be	  generated	  in	  the	  media.	  After	  the	  incubation	  period	  50	  µL	  of	  the	  media	  was	  placed	  in	  an	  opaque	  96	  well	  plate	  and	  mixed	  with	  25	  µL	  of	  2,3-­‐diaminonaphthalene	  (0.025	  mg/mL	  in	  0.62M	  HCl)	  and	  25	  µL	  of	  1.5	  M	  HCl.	  After	  incubation	  for	  30	  minutes	  at	  22	  °C	  10	  µL	  of	  3	  M	  NaOH	  was	  added	  to	  each	  well	  to	  quench	  the	  reaction.	  Fluorescence	  was	  measured	  using	  a	  Beckman	  Coulter,	  DTX	  880	  plate	  reader	  with	  Multimode	  Analysis	  Software	  and	  filters	  for	  excitation	  at	  365	  nm	  and	  emission	  at	  420	  nm.	  Raw	  fluorescence	  intensities	  were	  converted	  to	  nitrite	  concentration	  using	  a	  standard	  curve	  generated	  with	  known	  concentrations	  of	  sodium	  nitrite.	  Each	  data	  point	  represents	  an	  average	  of	  three	  samples	  and	  error	  bars	  indicate	  the	  standard	  deviation.	  
Co-­immunoprecipitation	  Assay.	  HEK293	  cells	  were	  virally	  transduced	  to	  express	  the	  soluble	  ectodomain	  of	  TLR4	  (1-­‐632)	  with	  a	  C-­‐terminal	  Fc	  tag	  (TLR4-­‐Fc).	  Dr.	  D.	  Golenbock	  graciously	  provided	  viral	  plasmids	  and	  the	  Fc	  construct	  used	  in	  this	  study.	  After	  viral	  transduction	  cells	  were	  maintained	  in	  DMEM	  media	  supplemented	  with	  10%	  FBS,	  penicillin	  (100	  U/mL),	  streptomycin	  (100	  μg/mL),	  geneticin	  (1	  mg/mL)	  and	  glutamine	  (2	  mM)	  with	  5%	  CO2	  at	  37°C.	  MD2	  protein	  was	  expressed	  from	  the	  vector	  pEF-­‐Bos-­‐MD-­‐2FLAG/6×	  His	  (MD2-­‐FLAG-­‐His)	  provided	  by	  Dr.	  Kensuke	  Miyake	  in	  HEK293t	  cells	  using	  DMEM	  media	  supplemented	  with	  10%	  FBS,	  penicillin	  (100	  U/mL),	  streptomycin	  (100	  μg/mL),	  and	  glutamine	  (2	  mM)	  with	  5%	  CO2	  at	  37°C.	  Detailed	  protocols	  for	  the	  expression	  and	  purification	  of	  both	  proteins	  have	  been	  previously	  described	  with	  a	  few	  modifications36.	  Lysis	  buffer	  for	  the	  cells	  was	  50	  mM	  Tris,	  160	  mM	  NaCl,	  5	  mM	  MgCl2,	  10%	  glycerol,	  1%	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Triton	  X-­‐100,	  and	  fresh	  protease	  inhibitor	  cocktail.	  TLR4-­‐Fc	  protein	  was	  captured	  with	  protein	  A	  sepharose	  (ThermoFisher),	  washed	  extensively	  in	  lysis	  buffer	  and	  eluted	  with	  Fc	  elution	  buffer	  (ThermoFisher).	  Eluted	  protein	  was	  dialyzed	  into	  fresh	  lysis	  buffer	  without	  the	  Triton	  X-­‐100.	  MD2-­‐FLAG-­‐His	  was	  purified	  under	  the	  same	  conditions	  with	  two	  exceptions:	  MD2-­‐FLAG-­‐His	  was	  immobilized	  on	  Ni-­‐NTA	  agarose	  (Qiagen)	  and	  eluted	  with	  lysis	  buffer	  containing	  300	  mM	  imidazole.	  Protein	  concentrations	  were	  determined	  using	  the	  Bradford	  assay.	  Purified	  TLR4	  ~100	  ng	  was	  mixed	  with	  25	  µL	  of	  protein	  A	  sepharose	  (ThermoFisher)	  and	  either	  200	  µM	  MD2-­‐I	  or	  MD2-­‐II.	  After	  a	  five	  minute	  incubation	  at	  4	  °C,	  	  ~50	  ng	  of	  MD2	  was	  added	  and	  incubated	  for	  another	  five	  minutes.	  After	  this	  incubation,	  the	  sepharose	  beads	  with	  precipitated	  protein	  were	  washed	  twice	  in	  lysis	  buffer,	  resuspended	  in	  sample	  buffer,	  boiled	  and	  resolved	  on	  SDS	  gels.	  Proteins	  were	  transferred	  to	  nitrocellulose	  membranes	  and	  blotted	  with	  either	  anti-­‐Fc	  or	  anti-­‐FLAG	  to	  stain	  TLR4	  or	  MD2	  respectively.	  A	  horseradish	  peroxidase	  secondary	  antibody	  was	  used	  along	  with	  a	  luminol	  detection	  kit	  (ThermoFisher)	  to	  detect	  the	  protein	  samples.	  The	  relative	  quantity	  of	  protein	  was	  determined	  using	  ImageJ	  software.	  
Results	  
Experimental	  Strategy	  and	  Peptide	  Synthesis.	  A	  17-­‐residue	  peptide	  (MD2-­‐I)	  was	  synthesized	  to	  reproduce	  the	  TLR4-­‐binding	  region	  of	  the	  MD2	  protein	  (Table	  1).	  We	  propose	  that	  the	  disulfide	  bridge	  between	  Cys95	  and	  Cys105	  and	  the	  secondary	  structures	  of	  the	  peptide	  help	  to	  retain	  the	  geometry	  of	  the	  critical	  residues	  in	  3D	  space	  and	  mimic	  that	  of	  the	  TLR4-­‐binding	  regions	  of	  the	  full-­‐length	  MD2.	  Previous	  studies	  with	  MD2	  mutants	  showed	  that	  the	  disulfide-­‐forming	  Cys95	  residue	  is	  critical	  for	  MD2	  binding	  TLR432.	  As	  such,	  a	  mutant	  MD2-­‐I	  peptide	  (MD2-­‐II)	  with	  Cys95	  replaced	  with	  an	  Ala	  residue	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was	  also	  synthesized.	  Formation	  of	  the	  disulfide	  bond	  in	  MD2-­‐I	  was	  verified	  with	  mass	  spectrometry	  and	  Ellman’s	  Reagent.	  All	  peptides	  used	  in	  this	  study	  were	  at	  least	  95%	  pure	  according	  to	  analytical	  HPLC.	  	  	  
Table	  2.1:	  Peptide	  sequences	  used	  in	  this	  study	  aligned	  against	  full-­‐length	  MD2.	  	  
Name	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sequence	  MD2	   90-­‐KEVICRGSDDDYSFCRALKGETVNTTISFS-­‐120	  MD2-­‐I	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CRGSDDDYSFCRALKGE	  MD2-­‐II	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ARGSDDDYSFCRALKGE	  Disulfide	  constraining	  cysteines	  shown	  in	  bold.	  Critical	  charged	  residues	  are	  underlined.	  
	  
Effect	  of	  MD2-­1	  on	  TLR4	  Initiated	  Signaling	  Cascades.	  To	  test	  the	  ability	  of	  MD2-­‐I	  to	  prevent	  TLR4	  initiated	  signaling,	  two	  different	  reporter	  gene	  assays	  were	  performed.	  First,	  HEK293	  cells	  stably	  expressing	  TLR4/MD2	  and	  a	  secreted	  alkaline	  phosphatase	  reporter	  gene	  (SEAP)	  located	  downstream	  from	  an	  NF-­‐κB	  promoter	  were	  tested.	  Cells	  were	  treated	  with	  a	  gradient	  of	  LPS	  ranging	  from	  0.01	  to	  100	  ng/mL	  to	  initiate	  TLR4	  signaling	  cascades	  and	  a	  constant	  dose	  of	  MD2-­‐I	  (100	  µM),	  MD2-­‐II	  (100	  µM),	  or	  LPS-­‐RS	  (200	  ng/mL,	  Figure	  2.2).	  Cells	  that	  were	  incubated	  with	  LPS	  show	  a	  level	  of	  SEAP	  activation	  that	  ranges	  from	  89	  ±	  11%	  at	  low	  concentration	  to	  401	  ±	  39%	  at	  high	  concentration	  when	  normalized	  to	  a	  blank	  control.	  Cells	  that	  were	  co-­‐incubated	  with	  MD2-­‐II	  show	  slightly	  reduced	  levels	  of	  activation	  (87	  ±	  5%	  –	  332  ±	  32%),	  but	  cells	  treated	  with	  MD2-­‐I	  show	  significantly	  reduced	  levels	  of	  activation	  even	  at	  high	  LPS	  concentration	  (101	  ±	  7%	  –	  193  ±	  20%).	  By	  comparison,	  the	  competitive	  LPS	  inhibitor	  LPS-­‐RS	  has	  no	  observable	  inhibitory	  activity	  at	  
	   20	  
the	  highest	  LPS	  concentration	  tested.	  Collectively,	  these	  results	  demonstrate	  that	  MD2-­‐I	  blocks	  LPS	  induced	  activation	  of	  TLR4	  signaling	  cascades	  while	  MD2-­‐II	  does	  not.	  Furthermore,	  the	  reduced	  level	  of	  maximum	  TLR4	  activation	  in	  the	  presence	  of	  MD2-­‐I	  indicates	  that	  MD2-­‐I	  does	  not	  act	  as	  a	  competitive	  inhibitor	  such	  as	  LPS-­‐RS.	  	  This	  result	  is	  consistent	  with	  MD2-­‐I	  targeting	  an	  allosteric	  site	  of	  the	  TLR4–MD2	  association,	  lending	  further	  support	  to	  the	  peptide	  inhibitor	  design.	  
Figure	  2.2:	  Suppression	  of	  TLR4	  signaling	  in	  SEAP	  reporter	  gene	  assay.	  Cells	  were	  planted	  in	  96-­‐well	  plates	  and	  allowed	  to	  recover	  24	  hours	  prior	  to	  experiment.	  On	  the	  day	  of	  experiment,	  media	  was	  replaced	  with	  CSF	  buffer	  containing	  either	  LPS	  (,	  0.01	  ng/mL	  to	  100	  ng/mL),	  LPS	  and	  MD2-­‐I	  (, 100	  µM),	  LPS	  and	  MD2-­‐II	  (,	  100	  µM),	  or	  LPS	  and	  LPS-­‐RS	  (,	  200	  ng/mL).	  After	  24	  hours,	  SEAP	  levels	  were	  quantitated	  using	  Applied	  Biosystems	  Phospha-­‐Light	  Chemiluminescent	  Reporter	  Gene	  Assay	  System	  according	  to	  manufacturer	  specifications.	  Data	  are	  expressed	  as	  normalized	  %  luminescence	  against	  a	  control	  sample	  that	  contains	  only	  buffer	  and	  peptide	  or	  buffer	  and	  LPS-­‐RS.	  	  	   To	  quantitate	  the	  inhibitory	  effect	  of	  MD2-­‐I,	  HEK	  cells	  were	  treated	  with	  a	  constant	  10	  ng/mL	  dose	  of	  LPS	  and	  titrated	  with	  increasing	  concentrations	  of	  MD2-­‐I	  or	  MD2-­‐II	  
	   21	  
(Figure	  2.3).	  Titration	  of	  MD2-­‐I	  led	  to	  a	  complete	  reduction	  in	  the	  levels	  of	  the	  SEAP	  reporter	  gene.	  The	  concentration	  of	  peptide	  required	  to	  reach	  50%	  of	  maximum	  activation	  is	  estimated	  at	  40	  µM	  from	  this	  data.	  Complete	  inhibition	  was	  accomplished	  at	  100	  µM	  peptide.	  In	  contrast	  to	  the	  robust	  inhibition	  observed	  with	  MD2-­‐I,	  MD2-­‐II	  did	  not	  have	  any	  observable	  inhibitory	  effect	  even	  at	  concentrations	  up	  to	  200	  µM.	   	  
Figure	  2.3:	  Titration	  of	  MD2-­‐I	  against	  LPS	  stimulated	  HEK293	  cells.	  HEK293	  cells	  stably	  expressing	  TLR4/MD2	  and	  a	  SEAP	  reporter	  gene	  were	  plated	  in	  96	  well	  plates	  24	  hours	  prior	  to	  experiment.	  On	  the	  day	  of	  experiment,	  cells	  were	  stimulated	  with	  10	  ng/mL	  LPS	  and	  titrated	  with	  increasing	  concentrations	  of	  MD2-­‐I	  ()	  or	  MD2-­‐II	  ().	  After	  24	  hours,	  SEAP	  levels	  were	  quantitated	  using	  Applied	  Biosystems	  Phospha-­‐Light	  Chemiluminescent	  Reporter	  Gene	  Assay	  System	  according	  to	  manufacturer	  specifications.	  Data	  are	  expressed	  as	  normalized	  %  luminescence	  against	  a	  control	  sample	  that	  contains	  only	  LPS.	  	  	  	   To	  test	  the	  effect	  of	  MD2-­‐I	  on	  a	  timescale	  more	  relevant	  signal	  transduction,	  a	  second	  reporter	  gene	  assay	  was	  carried	  out	  that	  utilizes	  an	  Akt1-­‐GFP	  reporter	  gene.	  In	  the	  presence	  of	  LPS	  this	  reporter	  gene	  is	  quickly	  trafficked	  from	  the	  cytosol	  to	  the	  membrane	  
	   22	  
and	  the	  cellular	  activation	  can	  be	  quantified	  by	  measuring	  the	  drop	  in	  cytosolic	  fluorescence	  as	  a	  function	  of	  time.	  Murine	  MD2	  has	  two	  mutations	  in	  the	  C95–E111	  binding	  loop	  (Arg96His,	  Ser98His).	  Neither	  of	  these	  mutations	  has	  been	  identified	  as	  a	  critical	  residue	  in	  the	  TLR4–MD2	  interaction,	  which	  suggests	  that	  human	  MD2	  peptides	  should	  function	  properly	  in	  the	  murine	  cell	  line33.	  RAW	  264.7	  cells	  transfected	  with	  the	  Akt1-­‐GFP	  reporter55	  were	  treated	  with	  MD2-­‐I	  or	  MD2-­‐II	  then	  activated	  with	  LPS.	  Cells	  that	  were	  treated	  with	  MD2-­‐I	  show	  almost	  no	  change	  in	  Akt1-­‐GFP	  diffusion	  when	  LPS	  is	  added	  (Figure	  2.4A).	  A	  small	  dose	  of	  complement	  5a	  (C5a,	  25	  ng/mL)	  confirms	  that	  these	  cells	  were	  active,	  but	  their	  ability	  to	  signal	  through	  TLR4	  was	  inhibited.	  MD2-­‐II	  did	  not	  show	  the	  same	  ability	  to	  block	  TLR4	  activation	  (Figure	  2.4B).	  After	  addition	  of	  LPS,	  these	  MD2-­‐II	  treated	  cells	  showed	  a	  very	  similar	  activation	  profile	  to	  untreated	  cells.	  Since	  Akt1	  is	  directly	  downstream	  of	  TLR4	  in	  the	  signal	  transduction	  pathway56,	  these	  data	  provide	  strong	  evidence	  that	  MD2-­‐I	  blocks	  TLR4-­‐mediated	  signaling	  by	  directly	  interacting	  with	  TLR4.	  Murine	  macrophages	  also	  express	  a	  variety	  of	  TLRs	  and	  immune	  receptors.	  Inhibiting	  LPS-­‐induced	  agonism	  of	  TLR4	  suggests	  that	  MD2-­‐I	  is	  specific	  for	  TLR4	  over	  other	  TLRs.	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Figure	  2.4:	  Comparison	  of	  MD2-­‐I	  and	  MD2-­‐II	  inhibition	  of	  LPS-­‐induced	  TLR4	  activation.	  Murine	  macrophages	  were	  treated	  with	  100	  μm	  (A)	  MD2-­‐I	  ()	  or	  (B)	  MD2-­‐II	  ()	  at	  35	  s.	  After	  two	  and	  a	  half	  minutes	  LPS	  was	  added	  to	  a	  final	  concentration	  of	  200	  ng/mL.	  If	  no	  visual	  response	  was	  observed	  after	  an	  additional	  two	  and	  a	  half	  minutes	  C5a	  (25	  ng/mL)	  was	  added	  to	  confirm	  that	  the	  cells	  were	  responsive	  (A).	  LPS	  response	  curve	  ()	  was	  collected	  with	  no	  peptide	  pretreatment.	  	  
Testing	  the	  Specificity	  of	  MD2-­I	  for	  TLR4.	  The	  specificity	  of	  MD2-­‐I	  was	  examined	  in	  an	  endogenous	  reporter	  gene	  assay	  was	  carried	  out	  using	  RAW267.4	  murine	  macrophages	  (Figure	  2.5).	  RAW	  cells	  robustly	  express	  a	  variety	  of	  toll-­‐like	  receptors.	  Moreover,	  these	  cells	  produce	  detectable	  amounts	  of	  the	  pro-­‐inflammatory	  mediator	  nitrite	  when	  agonized	  with	  TLR	  specific	  ligands.	  RAW	  cells	  were	  incubated	  with	  100	  µM	  MD2-­‐I	  and	  one	  of	  six	  TLR	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ligands	  specific	  for	  TLR4	  (LPS),	  TLR	  2/1	  (Pam3CKS4),	  TLR2/6	  (Peptidoglycan),	  TLR3	  (Poly(I:C)),	  TLR7	  (R848),	  and	  TLR9	  (ssDNA).	  Three	  concentrations	  of	  ligand	  were	  tested	  to	  initiate	  the	  production	  of	  nitrite	  over	  a	  linear	  range.	  	  Cells	  agonized	  with	  LPS	  show	  a	  significant	  drop	  in	  nitrite	  production	  when	  MD2-­‐I	  is	  present.	  TLR4	  signaling	  is	  inhibited	  by	  about	  75%	  at	  the	  two	  lowest	  LPS	  concentrations	  tested	  and	  50%	  at	  the	  highest	  LPS	  concentration.	  The	  decrease	  in	  inhibition	  of	  MD2-­‐I	  at	  the	  highest	  LPS	  concentration	  is	  somewhat	  troubling	  as	  the	  peptide	  inhibitor	  should	  be	  insensitive	  to	  LPS	  concentration	  (see	  Discussion).	  TLR1/2	  shows	  a	  small	  amount	  of	  inhibition	  (16-­‐30%)	  with	  MD2-­‐I	  at	  the	  two	  lowest	  concentrations	  tested,	  but	  no	  inhibition	  at	  the	  highest	  concentration.	  None	  of	  the	  other	  TLR	  ligands	  show	  any	  appreciable	  drop	  in	  nitrite	  production	  with	  MD2-­‐I	  present.	  MD2-­‐II	  is	  once	  again	  inactive	  against	  LPS	  induced	  TLR4	  signaling.	  Collectively,	  these	  results	  clearly	  demonstrate	  that	  the	  primary	  target	  for	  MD2-­‐I	  is	  TLR4	  and	  the	  presence	  of	  other	  TLRs	  do	  not	  alter	  this	  specificity.	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Figure	  2.5:	  Specificity	  of	  MD2-­‐I	  for	  TLR4.	  RAW	  264.7	  murine	  macrophages	  were	  plated	  in	  96	  well	  plates	  24	  hours	  prior	  to	  experiment	  to	  allow	  cells	  to	  recover.	  On	  the	  day	  of	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experiment	  cells	  were	  treated	  with	  the	  indicated	  concentrations	  of	  agonist	  to	  induce	  a	  linear	  increase	  in	  nitrite	  concentration	  (brown	  bars)	  or	  coincubated	  with	  either	  100	  µM	  MD2-­‐I	  (red	  bars)	  or	  100	  µM	  MD2-­‐2	  (blue	  bars).	  Cells	  were	  allowed	  to	  incubate	  with	  the	  additives	  for	  18	  hours	  after	  which	  samples	  of	  the	  media	  were	  collected	  and	  tested	  for	  nitrite	  concentration	  using	  2,3-­‐diaminonaphthalene.	  	  	  
Effect	  of	  MD2-­1	  on	  Extracellular	  TLR4/MD2	  Complexes	  Stimulated	  with	  LPS-­FITC.	  The	  inhibitory	  effect	  of	  MD2-­‐I	  on	  the	  TLR4/MD2	  complex	  was	  assessed	  by	  stimulating	  TLR4/MD2	  expressing	  HEK293	  cells	  with	  the	  exogenous	  TLR4	  ligand	  LPS.	  Cells	  were	  incubated	  with	  10	  μg/mL	  LPS	  that	  was	  conjugated	  with	  fluorescein	  isothiocyanate	  (LPS-­‐FITC)	  in	  the	  absence	  or	  presence	  of	  the	  MD2	  peptides	  and	  scanned	  in	  a	  flow	  cytometer.	  Cells	  that	  were	  incubated	  for	  two	  hours	  with	  LPS-­‐FITC	  are	  clearly	  labeled	  by	  the	  fluorescent	  ligand	  as	  indicated	  by	  the	  higher	  fluorescence	  intensity	  observed	  in	  these	  cells	  (Figure	  2.6A).	  Cells	  that	  were	  co-­‐incubated	  with	  LPS-­‐FITC	  and	  100	  µM	  MD2-­‐I	  are	  significantly	  less	  fluorescent	  after	  the	  two	  hour	  incubation,	  suggesting	  that	  MD2-­‐I	  is	  blocking	  LPS-­‐FITC	  from	  localizing	  to	  TLR4/MD2	  complexes	  on	  cell	  membranes	  (Figure	  2.6B).	  	  Cells	  that	  were	  co-­‐incubated	  with	  LPS-­‐FITC	  and	  MD2-­‐II	  appear	  to	  have	  the	  same	  fluorescence	  intensity	  as	  the	  LPS-­‐FITC	  control,	  suggesting	  that	  MD2-­‐II	  does	  not	  prevent	  LPS-­‐FITC	  from	  localizing	  to	  TLR4/MD2	  complexes	  (Figure	  2.6C).	  Given	  that	  MD2	  is	  the	  LPS	  binding	  molecule	  in	  TLR4/MD2	  complexes,	  one	  possible	  explanation	  for	  these	  results	  is	  that	  MD2-­‐I	  is	  binding	  to	  TLR4	  receptors	  and	  preventing	  MD2-­‐LPS	  complexes	  from	  interacting	  with	  these	  receptors.	  This	  hypothesis	  is	  supported	  by	  the	  observation	  that	  the	  cysteine	  knockout,	  MD2-­‐II	  has	  no	  effect	  on	  LPS	  labeling	  of	  TLR4/MD2	  complexes.	  Together,	  these	  results	  suggest	  that	  MD2-­‐I	  is	  interacting	  with	  TLR4	  at	  the	  same	  binding	  site	  as	  full-­‐length	  MD2	  and	  preventing	  the	  full-­‐length	  molecule	  from	  binding.	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Effect	  of	  MD2-­I	  and	  MD2-­II	  on	  TLR4/MD2	  Complexes	  In	  Vitro.	  To	  determine	  the	  ability	  of	  MD2-­‐I	  to	  block	  TLR4/MD2	  binding	  in	  vitro,	  a	  simple	  co-­‐immunoprecipitation	  assay	  was	  carried	  out	  using	  purified	  MD2	  and	  a	  soluble	  ectodomain	  fragment	  of	  TLR4	  (TLR4-­‐Fc).	  The	  TLR4-­‐Fc	  protein	  was	  immobilized	  on	  protein	  A	  sepharose	  beads	  and	  incubated	  with	  MD2-­‐I	  or	  MD2-­‐II	  to	  block	  MD2	  binding	  sites	  on	  the	  receptor.	  After	  a	  short	  incubation	  period	  full-­‐length	  MD2	  was	  added	  to	  the	  resin	  to	  see	  if	  MD2-­‐I	  could	  prevent	  its	  binding	  to	  TLR4.	  Samples	  incubated	  with	  MD2-­‐I	  show	  a	  70%	  reduction	  in	  MD2	  precipitation	  (Figure	  2.7).	  Samples	  incubated	  with	  MD2-­‐II	  show	  a	  modest	  decrease	  (27%)	  in	  MD2	  precipitation.	  This	  modest	  decrease	  with	  MD2-­‐II	  may	  arise	  from	  a	  number	  of	  sources.	  The	  high	  concentration	  of	  MD2-­‐II	  used	  in	  this	  experiment	  may	  be	  sufficient	  to	  allow	  MD2-­‐II	  to	  begin	  interacting	  with	  TLR4	  to	  some	  degree.	  Another	  option	  is	  nonspecific	  interactions	  between	  the	  peptide	  and	  either	  TLR4	  or	  MD2	  that	  prevent	  formation	  of	  the	  complex.	  At	  the	  very	  least	  these	  data	  suggest	  that	  MD2-­‐I	  is	  indeed	  directly	  inhibiting	  the	  formation	  of	  the	  TLR4/MD2	  complex.	  
	  	  
Figure	  2.7:	  Effect	  of	  MD2-­‐I	  and	  MD2-­‐II	  on	  TLR4/MD2	  complex	  formation	  in	  vitro.	  The	  soluble	  ectodomain	  of	  TLR4	  was	  expressed	  with	  a	  C-­‐terminal	  Fc	  tag	  and	  incubated	  with	  200	  µM	  MD2-­‐I	  or	  MD2-­‐II	  and	  protein	  A	  sepharose.	  After	  a	  five	  minute	  incubation	  period	  FLAG-­‐His-­‐MD2	  was	  added	  to	  the	  beads	  and	  incubated	  for	  5	  minutes.	  After	  five	  minutes	  the	  sepharose	  resin	  was	  gently	  washed,	  resuspended	  in	  sample	  buffer	  and	  boiled.	  Samples	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were	  resolved	  on	  SDS-­‐PAGE,	  transferred	  to	  nitrocellulose	  and	  blotted	  with	  either	  anti-­‐FC	  or	  anti-­‐FLAG	  antibodies.	  Raw	  data	  is	  shown	  to	  the	  right	  and	  densitometry	  of	  MD2	  bands	  is	  shown	  to	  the	  left.	  	  	  
Discussion	  This	  study	  utilized	  a	  17-­‐residue	  peptide,	  MD2-­‐I,	  derived	  from	  the	  TLR4	  binding	  residues	  on	  MD2	  to	  prevent	  TLR4	  signaling.	  The	  peptide	  incorporates	  a	  number	  of	  structural	  features	  that	  are	  important	  for	  MD2	  binding	  to	  TLR4.	  This	  study	  began	  by	  demonstrating	  that	  MD2-­‐I	  robustly	  inhibits	  TLR4	  signaling	  in	  a	  number	  of	  cell	  based,	  reporter	  gene	  assays,	  and	  attempted	  to	  characterize	  its	  mechanism	  of	  action.	  
MD2-­I	  Robustly	  Inhibits	  TLR4	  Signaling.	  To	  assess	  the	  ability	  of	  MD2-­‐I	  to	  inhibit	  LPS	  initiated	  TLR4	  signaling,	  three	  separate	  reporter	  gene	  assays	  were	  carried	  out.	  First,	  a	  HEK293	  cell,	  SEAP	  reporter	  gene	  assay	  was	  carried	  out	  to	  determine	  if	  MD2-­‐I	  could	  inhibit	  TLR4	  activation	  at	  a	  variety	  of	  LPS	  concentrations.	  The	  results	  clearly	  demonstrate	  that	  MD2-­‐I	  inhibits	  LPS	  initiated	  TLR4	  signaling	  by	  about	  50%.	  This	  inhibition	  is	  consistent	  over	  four	  orders	  of	  magnitude	  in	  LPS	  concentration.	  Even	  at	  the	  highest	  concentration	  of	  LPS	  tested	  (100	  ng/mL)	  MD2-­‐I	  reduced	  TLR4	  activity	  by	  more	  than	  half.	  The	  reduction	  in	  TLR4	  signaling	  across	  this	  wide	  array	  of	  LPS	  concentrations	  would	  seem	  to	  indicate	  that	  MD2-­‐I	  is	  inhibiting	  an	  allosteric	  site	  on	  TLR4	  and	  not	  competing	  directly	  for	  the	  LPS	  binding	  site.	  Utilizing	  the	  same	  reporter	  cells	  at	  a	  constant	  LPS	  dosage,	  inhibition	  of	  TLR4	  by	  MD2-­‐I	  was	  demonstrated	  to	  be	  dose	  dependent	  with	  a	  50%	  reduction	  in	  TLR4	  signaling	  at	  40	  µM	  peptide	  concentration	  and	  complete	  reduction	  at	  100	  µM	  peptide.	  Second,	  RAW264.7	  cells	  with	  an	  Akt1-­‐GFP	  reporter	  were	  utilized	  to	  determine	  if	  MD2-­‐I	  could	  inhibit	  TLR4	  signaling	  on	  a	  time	  scale	  relevant	  to	  cell	  signaling	  events.	  Addition	  of	  MD2-­‐I	  to	  these	  cells	  clearly	  prevented	  relocation	  of	  Akt1	  from	  the	  cytoplasm	  to	  the	  membrane,	  providing	  a	  clear	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indication	  that	  MD2-­‐I	  can	  inhibit	  TLR4	  quickly	  and	  on	  a	  time	  scale	  relevant	  to	  cell	  signaling	  events.	  Third,	  MD2-­‐I	  was	  tested	  against	  the	  same	  RAW264.7	  cells	  in	  a	  long-­‐term	  assay	  using	  endogenous	  nitrite	  production	  as	  the	  reporter.	  Impressively,	  MD2-­‐I	  inhibited	  TLR4	  signaling	  at	  three	  different	  LPS	  concentrations	  spanning	  three	  orders	  of	  magnitude.	  Furthermore,	  MD2-­‐I	  had	  little	  or	  no	  effect	  inhibiting	  TLR2/1,	  TLR2/6,	  TLR3,	  TLR7,	  and	  TLR9.	  A	  small	  reduction	  in	  the	  potency	  of	  MD2-­‐I	  was	  observed	  at	  the	  highest	  LPS	  concentration	  tested	  in	  this	  assay.	  This	  reduction	  may	  originate	  from	  a	  number	  of	  sources.	  Free	  cysteines	  in	  the	  culture	  media	  could	  break	  the	  C95-­‐C105	  disulfide	  rendering	  the	  peptide	  less	  active.	  This	  effect	  may	  not	  be	  observed	  at	  the	  lower	  concentrations	  of	  LPS	  because	  enough	  cyclized	  peptide	  is	  around	  to	  keep	  suppressing	  TLR4	  signaling.	  An	  alternative	  explanation	  is	  that	  impurities	  in	  the	  LPS	  are	  agonizing	  other	  TLRs,	  which	  MD2-­‐I	  is	  incapable	  of	  inhibiting.	  The	  same	  effect	  would	  not	  be	  observed	  in	  the	  HEK293	  cells	  as	  they	  do	  not	  express	  TLRs	  at	  a	  reasonable	  level.	  Collectively	  these	  reporter	  gene	  assays	  illustrate	  the	  robustness	  and	  specificity	  of	  MD2-­‐I	  at	  inhibiting	  TLR4	  signaling.	  Throughout	  all	  of	  these	  experiments	  the	  control	  peptide	  MD2-­‐II	  did	  not	  inhibit	  TLR4	  signaling	  suggesting	  that	  MD2-­‐I	  is	  indeed	  interacting	  with	  TLR4	  as	  it	  was	  designed.	  	  
MD2-­I	  Directly	  Interacts	  with	  TLR4.	  To	  determine	  if	  MD2-­‐I	  does	  indeed	  interact	  directly	  with	  TLR4,	  two	  competition	  assays	  were	  carried	  out.	  The	  first,	  utilizing	  TLR4	  expressing	  HEK293	  cells	  labeled	  with	  LPS-­‐FITC	  and	  the	  second,	  utilizing	  co-­‐immunoprecipitation	  of	  MD2	  by	  TLR4-­‐Fc.	  HEK293	  cells	  expressing	  TLR4	  and	  MD2	  were	  treated	  with	  LPS-­‐FITC	  and	  MD2-­‐I.	  Addition	  of	  MD2-­‐I	  to	  these	  cells	  caused	  a	  robust	  reduction	  in	  the	  labeling	  of	  cellular	  membranes	  with	  LPS-­‐FITC.	  MD2-­‐II	  did	  not	  produce	  the	  same	  effect	  and	  failed	  to	  prevent	  labeling	  of	  cells	  with	  LPS-­‐FITC.	  Precipitation	  of	  MD2	  by	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soluble	  TLR4-­‐Fc	  protein	  was	  also	  inhibited	  significantly	  (70%)	  by	  MD2-­‐I,	  although	  MD2-­‐II	  did	  show	  a	  little	  bit	  of	  inhibition	  in	  this	  assay	  as	  well	  (27%).	  The	  modest	  reduction	  in	  MD2	  precipitation	  by	  MD2-­‐II	  may	  originate	  from	  the	  relatively	  high	  concentration	  of	  peptide	  (200	  µM)	  used	  in	  this	  assay.	  Despite	  this	  modest	  reduction,	  MD2-­‐I	  is	  clearly	  the	  more	  potent	  inhibitor	  in	  vitro.	  Collectively	  these	  results	  inidcate	  that	  MD2-­‐I	  is	  indeed	  blocking	  the	  MD2	  binding	  site	  on	  TLR4	  and	  preventing	  TLR4	  activation.	  
Implications	  for	  TLR4	  Study	  and	  Drug	  Design.	  The	  studies	  carried	  out	  here	  describe	  a	  novel	  strategy	  for	  antagonizing	  TLR4.	  Directly	  blocking	  the	  TLR4/MD2	  interface	  provides	  a	  number	  of	  advantages	  over	  other	  strategies.	  First,	  blocking	  the	  TLR4/MD2	  interface	  inhibits	  signaling	  in	  a	  non-­‐competitive	  fashion,	  thereby	  reducing	  the	  maximum	  activation	  level	  of	  TLR4.	  This	  observation	  is	  particularly	  important	  as	  many	  TLR4	  inhibitors	  directly	  compete	  with	  LPS	  for	  the	  MD2	  binding	  site.	  These	  inhibitors	  are	  well	  documented	  for	  their	  lack	  of	  effectiveness	  and	  requirement	  of	  large	  doses37.	  Moreover,	  these	  competitive	  inhibitors	  must	  be	  extensively	  purified	  from	  bacterial	  sources	  or	  chemically	  synthesized.	  Both	  of	  these	  strategies	  are	  significantly	  more	  difficult	  than	  the	  automated	  process	  and	  high	  yields	  of	  peptide	  synthesis.	  Second,	  the	  MD2	  based	  peptide	  design	  incorporates	  a	  significant	  number	  of	  critical	  interacting	  residues	  and	  structural	  features	  from	  MD2.	  The	  incorporation	  of	  all	  of	  these	  structural	  elements	  into	  MD2-­‐I	  translates	  to	  robust	  inhibition	  in	  a	  number	  of	  assays.	  In	  constrast,	  utilizing	  a	  TLR4	  based	  peptide	  to	  block	  MD2	  binding	  was	  not	  quite	  as	  potent	  as	  MD2-­‐I,	  producing	  only	  50%	  reductions	  in	  TLR4	  signaling	  at	  very	  high	  peptide	  concentrations43.	  Third,	  the	  uniqueness	  of	  the	  TLR4/MD2	  interaction	  among	  toll-­‐like	  receptors	  makes	  this	  interaction	  a	  logical	  starting	  place	  for	  inhibitor	  design18.	  Additional	  inhibitors	  of	  TLR4	  have	  targeted	  the	  TIR	  dimerization	  interface	  and	  the	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interaction	  of	  TIR	  with	  MyD8839,	  44.	  While	  both	  of	  those	  inhibitors	  failed	  to	  produce	  any	  meaningful	  reduction	  of	  pro-­‐inflammatory	  cytokines	  in	  the	  clinic57,	  58,	  they	  are	  undoubtedly	  useful	  as	  tools	  to	  study	  TLR4.	  	  From	  this	  research	  perspective,	  MD2-­‐I	  fills	  in	  an	  important	  gap	  in	  TLR4	  inhibition.	  With	  the	  addition	  of	  MD2-­‐I,	  the	  collection	  of	  transient,	  reversible	  inhibitors	  of	  TLR4	  signaling	  can	  be	  accomplished	  at	  almost	  any	  level	  of	  TLR4	  activation:	  (1)	  LPS	  binding	  to	  MD2	  (Eritoran,	  LPS-­‐RS),	  (2)	  TLR4/MD2	  interaction	  (MD2-­‐I),	  (3)	  TIR-­‐Dimerization	  (TAK-­‐242),	  and	  TIR-­‐MyD88	  interaction	  (EM77,	  EM110)34,	  37,	  39,	  44.	  Moreover,	  this	  group	  now	  contains	  a	  variety	  of	  stable,	  but	  difficult	  to	  obtain	  molecules	  (TAK-­‐242,	  Eritoran,	  LPS-­‐RS)	  along	  with	  less	  stable,	  but	  more	  alterable	  peptides	  (MD2-­‐I,	  EM77,	  EM110).	  	  Taken	  together,	  the	  development	  of	  MD2-­‐I	  along	  with	  the	  host	  of	  other	  TLR4	  inhibitors	  have	  provided	  a	  number	  of	  useful	  tools	  for	  studying	  this	  unique	  receptor.	  Despite	  the	  shortcomings	  of	  some	  of	  these	  inhibitors	  clinically,	  the	  identification	  of	  the	  MD2	  binding	  site	  on	  TLR4	  as	  a	  target	  for	  inhibition	  provides	  a	  new	  avenue	  for	  small	  molecule	  development	  and	  future	  treatments	  for	  CNS	  diseases.	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Chapter	  3	  –	  Conclusions	  and	  Future	  Work	  on	  TLR4/MD2	  
Introduction.	  The	  first	  part	  of	  this	  work	  has	  focused	  on	  blocking	  the	  MD2	  binding	  site	  on	  TLR4	  as	  a	  strategy	  for	  preventing	  the	  assembly	  of	  the	  TLR4	  signaling	  complex	  and	  subsequent	  signaling	  events.	  Inhibition	  of	  the	  complex	  at	  this	  interface	  was	  accomplished	  with	  a	  17-­‐residue	  peptide:	  MD2-­‐I.	  This	  peptide	  incorporated	  a	  number	  of	  important	  charged	  residues	  and	  a	  constraining	  disulfide	  that	  allows	  full-­‐length	  MD2	  to	  interact	  with	  TLR4	  with	  low	  nanomolar	  affinity.	  The	  work	  presented	  here	  demonstrates	  that	  MD2-­‐I	  robustly	  inhibits	  TLR4	  signaling.	  Inhibition	  is	  TLR4	  specific	  and	  prevents	  TLR4	  initiated	  signaling	  cascades	  in	  short	  and	  long	  term	  experiments.	  Moreover,	  the	  designed	  mode	  of	  action	  of	  the	  peptide	  is	  confirmed	  by	  both	  flow	  cytometry	  and	  co-­‐immunoprecipitation	  experiments	  in	  vitro.	  In	  a	  broader	  sense,	  the	  experiments	  in	  this	  study	  establish	  the	  TLR4/MD2	  binding	  site	  as	  a	  new	  target	  for	  inhibition	  and	  confirm	  the	  importance	  of	  charged	  residues	  and	  the	  C95-­‐C105	  constraining	  disulfide	  in	  the	  TLR4/MD2	  interaction.	  	  The	  objective	  of	  this	  chapter	  is	  to	  discuss	  the	  results	  chapter	  2	  and	  suggest	  new	  experiments	  that	  will	  help	  characterize	  the	  TLR4/MD2	  interaction	  and	  develop	  new	  ways	  to	  inhibit	  this	  remarkable	  receptor.	  	  
Conclusions:	  Targeting	  the	  MD2	  binding	  site	  on	  TLR4	  with	  a	  17-­residue	  peptide	  that	  
incorporates	  the	  critical	  TLR4	  binding	  features	  of	  MD2	  is	  a	  successful	  strategy	  for	  inhibiting	  
formation	  of	  active	  TLR4/MD2	  signaling	  complexes.	  Recently,	  two	  different	  crystal	  structures	  of	  the	  TLR4/MD2	  interaction	  have	  been	  solved29,	  33.	  Both	  of	  these	  structures	  provided	  the	  structural	  insights	  for	  the	  design	  of	  MD2-­‐I.	  Robust	  inhibition	  of	  TLR4	  signaling	  was	  accomplished	  in	  a	  variety	  of	  assays	  using	  this	  peptide.	  In	  three	  separate	  cell	  reporter	  assays	  MD2-­‐I	  was	  demonstrated	  to	  prevent	  TLR4	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signaling.	  In	  HEK293	  cells	  containing	  an	  NF-­‐κB	  reporter	  gene,	  MD2-­‐I	  inhibited	  LPS	  induced	  TLR4	  signaling	  with	  50%	  efficiency	  at	  40	  µM	  peptide	  concentration.	  This	  reporter	  assay	  also	  demonstrated	  that	  MD2-­‐I	  works	  through	  a	  non-­‐competitive	  mode	  of	  inhibition,	  consistent	  with	  the	  peptide	  design.	  RAW264.7	  cells	  with	  an	  Akt1-­‐GFP	  promoter	  were	  used	  to	  show	  that	  MD2-­‐I	  inhibits	  TLR4	  signaling	  immediately	  after	  addition	  and	  on	  a	  timescale	  relevant	  to	  cell	  signaling	  events.	  MD2-­‐I	  was	  also	  tested	  in	  untransfected	  RAW264.7	  cells	  to	  determine	  if	  the	  peptide	  could	  block	  the	  endogenous	  production	  of	  nitrite.	  MD2-­‐I	  successfully	  inhibited	  the	  production	  of	  nitrite	  and	  did	  so	  in	  a	  TLR4	  specific	  fashion.	  Finally	  MD2-­‐I	  was	  tested	  for	  its	  ability	  to	  prevent	  MD2/TLR4	  association.	  In	  a	  flow	  cytometry	  experiment	  MD2-­‐I	  prevented	  LPS-­‐FITC-­‐MD2	  complexes	  from	  labeling	  the	  membranes	  of	  TLR4	  expressing	  HEK293	  cells.	  Furthermore,	  MD2-­‐I	  prevented	  the	  direct	  association	  of	  TLR4	  with	  MD2	  in	  vitro	  in	  a	  co-­‐immunoprecipitation	  experiment.	  	  The	  results	  presented	  here	  support	  a	  model	  where	  MD2-­‐I	  directly	  interacts	  with	  TLR4	  and	  prevents	  MD2	  from	  binding	  to	  the	  receptor.	  These	  findings	  are	  consistent	  with	  the	  peptide	  inhibitor	  design	  and	  suggest	  a	  new	  method	  for	  directly	  inhibiting	  TLR4.	  A	  more	  recent	  study	  showed	  that	  MD2-­‐I	  does	  bind	  directly	  to	  TLR4	  with	  an	  affinity	  of	  500	  nM59.	  This	  affinity	  is	  roughly	  50	  fold	  lower	  than	  full-­‐length	  MD2	  though	  still	  sufficient	  for	  a	  variety	  of	  biochemical	  experiments.	  	  The	  findings	  here	  fill	  in	  a	  large	  void	  in	  TLR4	  inhibition	  as	  none	  of	  the	  other	  inhibitors	  work	  directly	  on	  the	  TLR4/MD2	  association.	  	  
Proposed	  Future	  Studies.	  Unfortunately	  the	  peptide	  design	  suffers	  from	  some	  major	  drawbacks	  which	  could	  be	  fixed	  by	  modifying	  the	  peptide	  sequence.	  First,	  the	  disulfide	  bond	  is	  particularly	  labile	  in	  culture	  media	  due	  to	  disulfide	  exchange	  with	  free	  cysteines	  and	  also	  in	  the	  reductive	  environment	  of	  the	  cell.	  This	  simple	  drawback	  can	  be	  fixed	  by	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replacing	  the	  C95	  and	  C105	  with	  allylglycine	  and	  closing	  the	  ten	  residue	  ring	  with	  ring	  closing	  metathesis60.	  The	  subsequent	  carbon-­‐carbon	  double	  bond	  would	  be	  significantly	  less	  labile	  than	  the	  disulfide.	  Second,	  the	  sequence	  should	  be	  alanine	  scanned	  to	  determine	  which	  residues	  are	  particularly	  important	  for	  binding.	  Residues	  that	  are	  not	  critical	  for	  binding	  could	  be	  mutated	  to	  less	  protease	  sensitive	  residues60.	  This	  study	  is	  particularly	  important	  for	  the	  lysine,	  tyrosine,	  and	  phenylalanine	  residues	  in	  the	  sequence.	  If	  the	  residues	  cannot	  be	  mutated,	  another	  potential	  avenue	  is	  flipping	  the	  stereochemistry	  of	  the	  amino	  acid	  at	  that	  position60.	  This	  strategy	  may	  prove	  particularly	  useful	  as	  D	  amino	  acids	  resist	  proteolysis	  while	  preserving	  the	  side	  chain	  structure.	  Moreover,	  MD2-­‐I	  is	  undoubtedly	  flexible	  and	  may	  tolerate	  small	  backbone	  movements	  that	  allow	  the	  D	  amino	  acid	  side	  chains	  to	  compensate	  for	  the	  change	  in	  stereochemistry.	  In	  a	  broader	  sense	  this	  alanine	  scan	  would	  also	  be	  the	  first	  residue	  by	  residue	  scan	  of	  the	  TLR4	  binding	  region	  on	  MD2	  and	  may	  be	  useful	  in	  better	  understanding	  the	  structure	  and	  activation	  of	  the	  TLR4/MD2	  complex.	  Third,	  the	  peptide	  should	  be	  lengthened	  to	  include	  nearby	  residues	  on	  both	  the	  C	  and	  N	  termini.	  Residues	  upstream	  and	  downstream	  of	  MD2-­‐I	  are	  rich	  with	  hydrogen	  bonding	  and	  charged	  moieties.	  Many	  of	  these	  residues	  have	  not	  been	  tested	  in	  biochemical	  or	  molecular	  biological	  experiments.	  Incorporation	  of	  these	  residues	  onto	  the	  beginning	  or	  end	  of	  the	  sequence	  may	  lead	  to	  the	  discovery	  of	  new	  critical	  binding	  residues.	  Fourth	  and	  finally,	  a	  small	  molecule	  analog	  of	  approximate	  structure	  would	  certainly	  be	  a	  welcome	  substitute	  for	  the	  MD2-­‐I	  peptide.	  Unfortunately,	  the	  TLR4	  binding	  site	  is	  very	  broad	  and	  not	  significantly	  hydrophobic,	  suggesting	  that	  a	  small	  molecule	  analog	  may	  have	  difficulty	  reproducing	  the	  robust	  inhibition	  exhibited	  by	  MD2-­‐I.	  Some	  progress	  has	  been	  made	  to	  this	  end	  with	  the	  discovery	  of	  molecule	  2126.40,	  59	  This	  molecule	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has	  been	  shown	  to	  robustly	  prevent	  TLR4	  signaling	  and	  is	  very	  easily	  accessed	  by	  a	  three-­‐step	  chemical	  synthesis.	  In	  silico	  simulations	  have	  indicated	  that	  this	  molecule	  targets	  the	  MD2	  binding	  pocket	  on	  TLR4.	  However,	  the	  mode	  of	  action	  for	  this	  molecule	  has	  yet	  to	  be	  experimentally	  verified.	  	  Together,	  the	  future	  studies	  illustrated	  here	  would	  help	  to	  improve	  the	  stability	  of	  the	  peptide	  for	  use	  as	  a	  biochemical	  tool	  where	  transient,	  reversible	  inhibition	  of	  TLR4	  is	  desired	  and	  also	  help	  characterize	  TLR4/MD2	  interaction.	  These	  studies	  would	  be	  highly	  useful	  to	  scientists	  trying	  to	  understand	  the	  mechanism	  of	  TLR4	  activation	  and	  its	  involvement	  in	  a	  number	  of	  disease	  states.	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Chapter	  4	  -­	  Bacterial	  Chemotaxis	  and	  Unique	  Properties	  of	  Chemosensory	  Arrays	  
Two	  Component	  Systems.	  Two	  component	  signaling	  systems	  are	  the	  workhorses	  of	  intracellular	  signal	  transduction	  in	  prokaryotes	  and	  also	  appear	  in	  some	  lower	  eukaryotes.	  These	  systems	  are	  highly	  modular	  and	  provide	  a	  basic	  mechanism	  to	  couple	  environmental	  stimuli	  to	  cellular	  response61.	  The	  incorporation	  of	  these	  systems	  into	  a	  variety	  of	  cellular	  signaling	  circuits	  allows	  organisms	  to	  respond	  to	  a	  wide	  array	  of	  environmental	  stimuli	  including,	  pH,	  temperature,	  redox	  state,	  presence	  of	  nutrients,	  and	  many	  others62,	  63.	  	   At	  the	  core	  of	  prokaryotic	  two	  component	  systems	  are	  Histidine	  Kinases	  (HKs)	  and	  Response	  Regulator	  proteins	  (RRs)	  (Figure	  4.1).	  HKs	  are	  typically	  fused	  or	  associated	  with	  a	  transmembrane	  receptor.	  Sensing	  of	  an	  extracellular	  stimulus	  by	  the	  receptor	  regulates	  the	  activity	  of	  the	  HK.	  In	  a	  typical	  system,	  the	  HK	  will	  first	  phosphorylate	  itself	  on	  a	  conserved	  histidine	  residue64.	  A	  RR	  will	  catalyze	  the	  transfer	  of	  phosphate	  from	  the	  HK	  to	  a	  well-­‐conserved	  aspartate	  residue	  on	  the	  RR.	  The	  phosphorylated	  RR	  then	  directs	  a	  particular	  cellular	  response65.	  	  	  
	  
Figure	  4.1:	  Architecture	  of	  two-­‐component	  systems.	  Named	  for	  their	  two	  conserved	  kinases	  (histidine	  and	  aspartate).	  Most	  of	  these	  systems	  couple	  the	  histidine	  kinase	  to	  a	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receptor	  that	  senses	  environmental	  stimuli	  and	  regulates	  the	  activity	  of	  the	  histidine	  kinase.	  The	  phosphorylated	  histidine	  kinase	  serves	  as	  the	  substrate	  for	  phosphotransfer	  to	  the	  aspartate	  kinase.	  The	  phosphorylated	  aspartate	  kinase	  directs	  a	  physiological	  output.	  Dephosphorylation	  of	  the	  aspartate	  is	  accomplished	  by	  cellular	  phosphatases	  or	  by	  autodephosphorylation66.	  	  	   One	  of	  the	  best	  characterized	  two	  component	  systems	  is	  the	  chemosensory	  system	  of	  E.	  coli.	  The	  chemosensory	  system	  biases	  bacterial	  movement	  up	  gradients	  of	  attractants	  or	  down	  gradients	  of	  repellants.	  The	  conservation	  of	  this	  system	  across	  a	  wide	  range	  of	  bacteria	  makes	  it	  an	  attractive	  model	  system	  for	  studying	  the	  molecular	  changes	  that	  regulate	  complex	  cellular	  behaviors62.	  
Bacterial	  Chemotaxis.	  Directing	  movement	  towards	  the	  best	  environment	  is	  critically	  important	  for	  bacterial	  survival.	  Bacteria	  constantly	  sense	  chemical	  gradients	  in	  their	  environment	  and	  bias	  their	  movements	  towards	  the	  most	  favorable	  environments	  and	  away	  from	  the	  least	  favorable	  environments.	  This	  behavior	  is	  referred	  to	  as	  bacterial	  chemotaxis67.	  	   Different	  bacteria	  exhibit	  a	  wide	  range	  of	  methods	  for	  locomotion	  while	  sharing	  a	  conserved	  chemotaxis	  pathways.	  E.	  coli	  is	  the	  prototypical	  system	  for	  investigating	  how	  bacteria	  can	  chemotax	  towards	  the	  best	  environment.	  E.	  coli	  have	  two	  basic	  behaviors:	  tumbling	  and	  running	  smoothly.	  Tumbling	  corresponds	  to	  a	  clockwise	  rotation	  of	  the	  flagella	  while	  running	  corresponds	  to	  a	  counterclockwise	  rotation.	  Bacteria	  constantly	  alternate	  between	  these	  behaviors	  every	  one	  or	  two	  seconds.	  The	  direction	  in	  which	  the	  bacterium	  chooses	  to	  run	  is	  random	  so	  in	  the	  absence	  of	  chemical	  gradients	  bacterial	  motion	  executes	  a	  random	  3D	  walk.	  	  However,	  in	  the	  presence	  of	  a	  chemical	  gradient,	  the	  duration	  of	  a	  run	  is	  extended	  if	  the	  bacterium	  is	  moving	  in	  a	  favorable	  direction.	  	  Extending	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the	  duration	  of	  runs	  in	  the	  favorable	  direction	  yields	  a	  biased	  random	  walk	  that	  moves	  the	  bacteria	  towards	  the	  best	  environment	  (Figure	  4.2)68.	  	  	  
	  
Figure	  4.2:	  The	  biased	  random	  walk	  of	  E.	  coli.	  Bacteria	  randomly	  alternate	  between	  tumbles	  and	  runs	  corresponding	  to	  clockwise	  (CW)	  or	  counterclockwise	  (CCW)	  rotation	  of	  the	  flagella	  respectively.	  A,	  In	  the	  absence	  of	  a	  chemical	  gradient	  alternating	  between	  tumbles	  and	  runs	  yields	  no	  net	  migration.	  B,	  In	  the	  presence	  of	  attractant	  or	  repellant	  gradients,	  runs	  that	  carry	  the	  bacteria	  in	  a	  favorable	  direction	  are	  extended.	  Runs	  that	  carry	  the	  bacteria	  in	  an	  unfavorable	  direction	  are	  minimized.	  Extending	  the	  duration	  of	  the	  runs	  in	  favorable	  direction	  yields	  a	  biased	  migration	  up	  an	  attractant	  gradient	  or	  down	  a	  repellant	  gradient.	  	  	   Bacterial	  Chemosensing	  Pathway.	  E.	  coli	  and	  a	  number	  of	  other	  bacteria	  utilize	  a	  large	  supramolecular	  complex	  to	  sense	  chemical	  gradients.	  This	  complexes	  consists	  of	  thousands	  of	  chemosensory	  receptors	  coupled	  to	  signal	  transduction	  proteins.	  The	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complex	  senses	  and	  responds	  to	  temporal	  changes	  in	  the	  extracellular	  environment	  and	  modulates	  the	  rotation	  of	  the	  flagella	  to	  bias	  bacterial	  motion66,	  67.	  	  Bacterial	  chemosensing	  starts	  in	  the	  periplasmic	  space	  at	  a	  membrane	  bound	  protein	  known	  as	  a	  methyl-­‐accepting	  chemotaxis	  protein	  or	  MCP.	  The	  two	  most	  common	  MCPs	  in	  E.	  coli	  are	  the	  transmembrane	  serine	  receptor	  (Tsr)	  and	  the	  transmembrane	  aspartate	  receptor	  (Tar).	  Tsr	  is	  expressed	  about	  100	  fold	  higher	  than	  low	  abundance	  MCPs	  and	  senses	  the	  attractant	  serine	  or	  the	  repellant	  phenol.	  Tar	  is	  expressed	  about	  10	  fold	  more	  than	  low	  abundance	  MCPs	  and	  senses	  the	  attractants	  aspartate	  and	  galactose	  as	  well	  as	  the	  repellant	  nickel66,	  69,	  70.	  Additional	  MCPs	  are	  the	  receptors	  for	  ribose	  and	  galactose	  (Trg),	  dipeptides	  (Tap),	  citrate	  (Tcp),	  and	  oxygen	  (Aer).	  	  Thousands	  of	  these	  receptors	  cluster	  together	  to	  form	  extended	  hexagonal	  arrays	  that	  serve	  as	  a	  platform	  for	  the	  assembly	  of	  other	  chemotaxis	  proteins.	  At	  the	  cytoplasmic	  tip	  of	  these	  receptors	  is	  a	  binding	  site	  for	  the	  HK,	  CheA.	  CheA	  interacts	  directly	  with	  the	  receptor	  through	  a	  hydrophobic	  patch	  and	  also	  through	  a	  coupling	  protein,	  CheW.	  MCPs,	  CheA,	  and	  CheW	  form	  the	  simplest	  core	  unit	  necessary	  for	  bacterial	  chemotaxis71-­‐73.	  	  	   The	  unoccupied,	  apo	  receptor	  activates,	  thereby	  stimulating	  autophosphorylation	  of	  its	  conserved	  histidine	  residue.	  The	  RR,	  CheY,	  binds	  to	  CheA	  and	  transfers	  the	  phosphate	  group	  from	  CheA	  to	  an	  aspartate	  residue	  on	  itself.	  Phospho-­‐CheY	  dissociates	  from	  CheA	  and	  diffuses	  to	  the	  flagella	  where	  it	  binds	  the	  motor	  protein	  FliM	  and	  increases	  the	  probability	  for	  clockwise	  rotation	  (tumbling)74.	  	  CheY	  is	  constantly	  dephosphorylated	  by	  the	  phosphatase	  CheZ.	  The	  rapid	  turnover	  of	  phospho-­‐CheY	  by	  CheZ	  ensures	  that	  the	  pathway	  can	  rapidly	  respond	  to	  environmental	  changes(Figure	  4.3).	  Binding	  of	  an	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attractant	  to	  the	  MCP	  quickly	  inhibits	  CheA	  kinase	  activity,	  causing	  a	  drop	  in	  phospho-­‐CheY	  and	  an	  increase	  in	  counterclockwise	  motion	  (smooth	  swimming).	  
	  
Figure	  4.3:	  The	  chemosensory	  pathway	  of	  bacterial	  chemotaxis.	  A	  representative	  Gram	  negative	  bacterium	  is	  shown.	  The	  periplasmic	  space	  is	  depicted	  in	  blue	  and	  the	  cytoplasm	  is	  depicted	  in	  purple.	  Membrane	  bound	  apo-­‐receptors	  activate	  receptor	  bound	  CheA.	  CheA	  kinase	  phosphorylates	  itself	  on	  a	  conserved	  histidine	  residue.	  The	  response	  regulator	  CheY	  binds	  CheA	  and	  transfer	  the	  phosphate	  to	  itself.	  Phospho-­‐CheY	  diffuses	  to	  flagella	  where	  it	  increases	  the	  probability	  for	  clockwise	  motion.	  The	  phosphatase	  CheZ	  desphosphorylates	  CheY	  ensuring	  that	  the	  pathway	  response	  time	  is	  short.	  The	  methylase	  CheR	  is	  constitutively	  active	  and	  methylates	  receptors	  at	  one	  of	  four	  glutamate	  side	  chains.	  The	  response	  regulator	  CheB	  catalyzes	  the	  transfer	  of	  phoshate	  from	  CheA	  to	  itself	  and	  phospho-­‐CheB	  demethylates	  the	  methylated	  glutamates.	  Binding	  of	  attractant	  to	  receptor	  turns	  off	  CheA	  kinase	  leading	  to	  a	  rapid	  depletion	  in	  both	  phospho-­‐CheY	  and	  and	  phospho-­‐CheB,	  increasing	  the	  probability	  for	  counter-­‐clockwise	  rotation.	  	  	   In	  addition	  to	  this	  simple	  signaling	  circuit,	  the	  activity	  of	  MCPs	  is	  modulated	  through	  an	  adaptation	  system.	  This	  system	  allows	  bacteria	  to	  adjust	  their	  sensitivity	  to	  chemical	  attractants	  and	  also	  serves	  as	  a	  short-­‐term	  chemical	  memory	  to	  determine	  if	  the	  current	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swimming	  direction	  is	  favorable	  or	  unfavorable.	  Adaption	  is	  controlled	  by	  methylating	  or	  demethylating	  four	  conserved	  glutamate	  side	  chains	  on	  MCPs.	  Natively,	  two	  of	  these	  residues	  are	  expressed	  as	  neutral	  glutamines	  (Q297,	  Q311)	  and	  two	  as	  negative	  glutamates	  (E304,	  E493).	  Methylation	  of	  these	  glutamates	  neutralizes	  charge	  and	  leads	  to	  more	  cooperative	  MCPs	  that	  are	  less	  sensitive	  to	  attractant.	  Demethylation	  (or	  deamidation)	  increases	  charge	  and	  repulsion	  between	  neighboring	  MCPs	  causing	  the	  receptors	  to	  be	  less	  cooperative	  and	  more	  sensitive	  to	  attractant75.	  The	  adapation	  enzymes	  CheR	  and	  CheB	  control	  methylation	  and	  demethylation	  respectively.	  CheR	  is	  a	  constitutively	  active	  methyl	  esterase	  and	  is	  localized	  to	  MCPs	  by	  a	  flexible,	  c-­‐terminal	  pentapeptide	  sequence.	  CheB	  is	  a	  RR	  that	  is	  phosphorylated	  by	  CheA76.	  Once	  phosphorylated	  CheB	  actively	  demethylates	  receptor	  glutamate	  side	  chains77.	  Modulation	  of	  receptor	  sensitivity	  through	  this	  negative	  feedback	  loop	  allows	  bacteria	  to	  respond	  to	  attractant	  concentrations	  over	  four	  orders	  of	  magnitude78.	  
Localization	  and	  architecture	  of	  the	  chemotaxis	  signaling	  array.	  A	  number	  of	  imaging	  techniques	  have	  provided	  insight	  into	  the	  cellular	  location	  and	  the	  architecture	  of	  chemosensory	  arrays79-­‐81.	  The	  core	  components	  of	  chemosensory	  arrays	  (MCPs,	  CheA,	  CheW)	  and	  many	  of	  the	  adaptation	  or	  signaling	  proteins	  (CheR,	  CheB,	  CheY,	  CheZ,	  etc.)	  are	  predominantly	  localized	  at	  the	  cell	  poles.	  In	  contrast,	  flagellar	  motors	  are	  randomly	  distributed	  around	  the	  bacterial	  membrane.	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Figure	  4.4:	  Localization	  of	  bacterial	  chemosensory	  arrays.	  Yellow-­‐fluorescent	  protein	  fusions	  to	  CheA	  (A)	  and	  CheW	  (B)	  localize	  to	  bacterial	  chemosensory	  arrays.	  Bright	  yellow	  spots	  on	  the	  surface	  of	  the	  bacteria	  indicate	  the	  location(s)	  of	  arrays.	  Arrays	  are	  localized	  predominantly	  at	  the	  poles	  of	  bacteria	  in	  areas	  of	  high	  membrane	  curvature.	  Arrays	  are	  also	  located	  on	  the	  lateral	  surfaces	  of	  bacteria	  at	  potential	  cell	  division	  sites.	  	  	  	   Cryo-­‐electron	  tomography	  studies	  have	  revealed	  that	  chemosensory	  arrays	  from	  a	  range	  of	  distantly	  related	  bacteria	  share	  a	  common	  architecture.	  Thousands	  of	  MCPs	  are	  arranged	  in	  a	  repeating	  hexagonal	  pattern.	  At	  the	  vertex	  of	  each	  hexagon	  are	  six	  receptor	  monomers	  arranged	  into	  a	  trimer	  of	  receptor	  dimers.	  The	  spacing	  between	  these	  hexagons	  is	  a	  consistent	  12	  nm	  measured	  from	  center	  of	  one	  hexagon	  to	  the	  next	  (Figure	  4.5).	  At	  the	  cytoplasmic	  tip	  of	  the	  receptors	  is	  a	  significant	  layer	  of	  high	  electron	  density	  corresponding	  to	  receptor	  bound	  CheA	  and	  CheW82,	  83.	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Figure	  4.5:	  Assembly	  of	  receptors	  in	  arrays.	  Crystal	  structures	  of	  a	  soluble	  cytoplasmic	  fragment	  of	  Tsr	  from	  E.	  Coli	  are	  depicted	  here84.	  Receptor	  monomers	  dimerize	  (blue	  and	  orange)	  and	  assemble	  into	  trimers-­‐of-­‐dimers	  with	  extensive	  contacts	  at	  the	  membrane	  distal	  tip	  of	  the	  receptor	  fragments85,	  86.	  Trimers-­‐of-­‐dimers	  form	  densely	  packed	  hexagonal	  arrays	  with	  one	  trimer	  at	  each	  hexagonal	  vertex87.	  	  	  	   Combining	  low-­‐resolution	  imaging	  with	  high	  resolution	  techniques	  has	  provided	  the	  current	  model	  of	  the	  various	  interactions	  between	  MCPs,	  CheW	  and	  the	  five	  domains	  of	  CheA	  (N-­‐P1-­‐P2-­‐P3-­‐P4-­‐P5-­‐C)87-­‐90.	  Adjacent	  receptor	  trimers	  in	  one	  hexagon	  each	  align	  two	  of	  their	  dimers	  towards	  one	  another.	  	  Each	  CheA	  dimer	  interacts	  with	  two	  CheW	  molecules	  using	  the	  P5	  domains.	  The	  helical,	  dimerization	  domain	  of	  CheA	  (P3)	  is	  packed	  between	  the	  receptors.	  Hydrophobic	  patches	  on	  the	  P5	  domain	  of	  CheA	  and	  CheW	  interact	  with	  corresponding	  hydrophobic	  patches	  on	  receptors.	  Both	  CheA	  and	  CheW	  interact	  with	  receptors	  at	  the	  same	  sites	  but	  on	  adjacent	  dimers.	  The	  hexagonal	  architecture	  of	  the	  array	  creates	  an	  interconnected	  ring	  of	  CheA-­‐CheW	  dimers	  that	  are	  attached	  nose	  to	  tail.	  One	  consequence	  of	  this	  architecture	  is	  that	  the	  CheA-­‐CheW	  ring	  will	  only	  fit	  in	  every	  other	  hexagon.	  The	  remaining	  hexagons	  are	  hypothesized	  to	  contain	  CheW	  rings,	  which	  would	  help	  explain	  the	  observation	  that	  CheA:CheW	  ratio	  is	  less	  than	  1:1	  in	  arrays88,	  91-­‐93.	  The	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remaining	  domains	  of	  CheA	  (P1,	  P2,	  and	  P4)	  sit	  largely	  beneath	  the	  plane	  of	  receptors.	  The	  P1	  and	  P2	  domains	  (not	  shown	  here)	  are	  connected	  by	  highly	  flexible	  linkers	  and	  their	  positions	  in	  the	  array	  have	  not	  been	  assigned	  (Figure	  4.6).	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Figure	  4.6:	  Structural	  model	  of	  CheA,	  CheW,	  and	  MCPs	  in	  chemosensory	  arrays.	  	  Two	  MCP	  trimers-­‐of-­‐dimers	  (orange/blue)	  interact	  with	  one	  CheA	  homodimer	  (green)	  and	  two	  CheW	  proteins	  (salmon).	  Side	  view	  and	  bottom	  view	  are	  shown.	  Six	  trimers-­‐of-­‐dimer	  interact	  with	  three	  CheA	  homodimers	  and	  six	  CheW	  proteins	  creating	  an	  interconnected	  ring.	  Bottom	  view	  shown	  here.	  Hexagons	  consisting	  of	  MCPs,	  CheA,	  and	  CheW	  are	  propagated	  throughout	  an	  extended	  model	  array.	  Empty	  rings	  are	  hypothesized	  to	  contain	  CheW	  rings87,	  94.	  	  
Unique	  Properties	  of	  Chemosensory	  Arrays.	  The	  recent	  advances	  in	  understanding	  the	  structure	  of	  chemosensory	  arrays	  are	  beginning	  to	  reveal	  the	  molecular	  mechanisms	  behind	  some	  unique	  properties	  of	  these	  arrays.	  Three	  of	  the	  most	  intriguing	  properties	  are	  significant	  positive	  cooperativity,	  a	  high	  gain	  in	  signal	  amplification	  and	  a	  striking	  ultra-­‐stability	  in	  vitro.	  	  Chemosensory	  arrays	  exhibit	  high	  positive	  cooperativity	  in	  kinase	  signaling75,	  91.	  Hill	  coefficients	  for	  reconstituted	  Tsr	  arrays	  in	  vitro	  range	  from	  1.7	  for	  the	  fully	  demethylated,	  EEEE	  receptor	  to	  6.8	  for	  the	  fully	  modified	  QQQQ	  receptor.	  Measurements	  in	  vivo	  are	  slightly	  higher	  with	  a	  range	  from	  3	  to	  10	  depending	  on	  the	  modification	  state95.	  	  The	  high	  degree	  of	  interconnectivity	  between	  CheA	  and	  CheW	  in	  the	  hexameric	  rings	  of	  the	  array	  provides	  a	  simple	  model	  for	  explaining	  the	  propagation	  of	  a	  ligand-­‐sensing	  event	  through	  multiple	  kinases.	  This	  model	  is	  also	  consistent	  with	  the	  observation	  that	  cooperativity	  in	  the	  array	  arises	  at	  the	  CheA	  kinase	  level	  and	  not	  higher	  up	  on	  the	  receptor	  in	  the	  methylation	  region96.	  The	  cooperativity	  between	  receptors	  together	  with	  other	  features,	  yields	  a	  large	  signal	  amplification	  between	  ligand	  occupancy	  and	  rotational	  bias	  of	  the	  flagella.	  Cells	  respond	  to	  as	  little	  as	  10	  nM	  aspartate	  in	  solution,	  a	  concentration	  that	  is	  equivalent	  to	  about	  10	  aspartate	  molecules	  over	  the	  volume	  of	  the	  bacterial	  cell.	  The	  change	  in	  receptor	  occupancy	  with	  this	  small	  addition	  of	  aspartate	  should	  be	  less	  than	  0.2%.	  However,	  the	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change	  in	  rotational	  bias	  of	  the	  flagella	  is	  23%,	  indicating	  a	  100-­‐fold	  gain	  in	  signal	  amplification97.	  At	  the	  chemosensory	  array	  level	  specifically,	  the	  gain	  in	  signal	  amplification	  due	  to	  cooperativity	  is	  roughly	  35	  fold97,	  98.	  Moreover,	  the	  35	  fold	  amplification	  scales	  linearly	  over	  two	  orders	  of	  attractant	  magnitude99.	  This	  striking	  signal	  amplification	  also	  supports	  the	  idea	  of	  a	  highly	  ordered	  and	  highly	  interconnected	  array.	  	  Chemosensory	  arrays	  display	  a	  striking	  ultra-­‐stability	  in	  vitro92.	  	  Arrays	  consisting	  of	  Tsr,	  CheA,	  and	  CheW	  reconstituted	  in	  vitro	  or	  assembled	  in	  vivo	  retain	  their	  kinase	  activity,	  ligand	  sensitivity,	  and	  the	  relative	  stoichiometry	  of	  their	  components	  for	  at	  least	  24	  hours	  in	  vitro.	  Longer	  timecourses	  have	  revealed	  that	  arrays	  can	  retain	  their	  stoichiometry	  and	  activity	  for	  up	  to	  five	  days,	  even	  at	  very	  high	  dilution.	  Array	  bound	  CheA	  and	  CheW	  also	  do	  not	  appear	  to	  exchange	  in	  and	  out	  of	  the	  array	  but	  rather	  remain	  tightly	  bound	  to	  the	  array	  even	  in	  the	  presence	  of	  excess	  CheA	  and	  CheW	  in	  solution.	  These	  results	  also	  suggest	  that	  array	  bound	  components	  are	  highly	  ordered	  and	  interconnected,	  forming	  a	  nearly	  covalent	  interaction.	  Measurements	  of	  CheA	  and	  CheW	  exchange	  rates	  in	  vivo	  suggest	  that	  the	  lifetime	  of	  these	  components	  in	  the	  array	  is	  significantly	  shorter	  (~12	  minutes)100.	  While	  significantly	  shorter	  than	  the	  in	  vitro	  stability,	  the	  12	  minute	  array	  lifetime	  is	  still	  roughly	  70%	  of	  the	  E.	  Coli	  lifetime101.	  However,	  these	  findings	  do	  suggest	  that	  a	  chaperone	  or	  protease—not	  present	  in	  vitro—may	  actively	  degrade	  CheA	  and	  CheW	  in	  chemosensory	  arrays	  in	  vivo.	  Alternatively,	  the	  fluorescent	  fusion	  proteins	  used	  to	  monitor	  exchange	  in	  vivo	  may	  perturb	  the	  system	  to	  yield	  faster	  dissociation	  than	  normal.	  	  Chapter	  5	  begins	  with	  a	  thorough	  characterization	  of	  the	  decay	  kinetics	  of	  these	  remarkable	  chemosensory	  arrays	  and	  follows	  with	  an	  investigation	  of	  the	  origin	  of	  ultra-­‐stability.	  Chapter	  6	  concludes	  with	  a	  new	  mosaic	  model	  of	  chemosensory	  arrays.	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Chapter	  5	  -­	  Investigating	  the	  Mechanism	  of	  Ultra-­stability	  in	  	  
Bacterial	  Chemosensory	  Arrays	  
	  
Abstract	  	   Bacteria	  utilize	  large	  multi-­‐protein	  chemosensory	  arrays	  to	  sense	  attractants	  and	  repellants	  in	  their	  environment.	  	  The	  essential	  components	  of	  these	  arrays	  are	  hexagonally	  arranged	  core	  units	  consisting	  of	  receptor	  trimer-­‐of-­‐dimers,	  CheA	  histidine	  kinase,	  and	  CheW	  coupling	  protein.	  	  Incorporation	  of	  these	  units	  into	  arrays	  has	  several	  advantages	  including	  strong	  cooperativity	  and	  high	  sensitivity	  in	  ligand	  sensing,	  a	  large	  dynamic	  range	  and	  rapid	  signal	  transduction	  through	  the	  signalling	  circuit.	  	  Another	  unique	  advantage	  of	  the	  array	  architecture	  is	  a	  striking	  ultra-­‐stability	  in	  
vitro	  with	  arrays	  retaining	  kinase	  activity,	  attractant	  sensitivity	  and	  bound	  components	  for	  weeks.	  This	  work	  examines	  this	  remarkable	  ultra-­‐stability	  and	  its	  origin	  in	  more	  detail.	  The	  results	  of	  this	  study	  demonstrate	  that	  arrays	  are	  not	  homogenous,	  but	  rather	  exhibit	  two	  or	  more	  major	  populations.	  One	  population	  is	  quasi-­‐stable	  with	  a	  lifetime	  of	  1-­‐2	  days,	  and	  loss	  of	  this	  population	  is	  highly	  correlated	  with	  a	  slow	  proteolytic	  degradation	  of	  CheA	  kinase.	  The	  second	  population	  is	  truly	  ultra-­‐stable	  with	  a	  lifetime	  of	  20	  days	  or	  more,	  and	  is	  less	  accessible	  to	  proteolysis.	  Following	  degradation	  of	  the	  less	  stable	  population,	  the	  cooperativity	  of	  the	  array	  increases,	  arguing	  that	  the	  less	  stable	  regions	  of	  array	  are	  not	  as	  well	  ordered	  and	  cooperative	  as	  the	  ultra-­‐stable	  regions.	  To	  test	  the	  hypothesis	  that	  a	  well-­‐ordered	  array	  is	  required	  for	  ultra-­‐stability,	  we	  have	  introduced	  a	  small	  density	  of	  defects	  into	  the	  complex	  through	  chemical	  modification.	  	  Notably,	  even	  a	  very	  low	  degree	  of	  packing	  defects	  can	  abolish	  array	  ultra-­‐stability,	  supporting	  the	  hypothesis.	  These	  findings	  are	  consistent	  with	  a	  model	  in	  which	  cooperativity	  and	  ultra-­‐stability	  arise	  from	  extensive	  interconnectivity	  between	  multiple	  components	  within	  a	  well-­‐ordered	  array.	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Introduction	  	   Two-­‐component	  systems	  are	  the	  predominant	  signalling	  pathways	  utilized	  in	  bacteria	  and	  other	  prokaryotes.	  At	  the	  simplest	  level,	  two	  component	  systems	  contain	  a	  HK	  fused	  or	  bound	  to	  a	  transmembrane	  receptor	  and	  a	  RR61.	  Bacteria	  have	  adapted	  these	  two	  component	  systems	  to	  sense	  chemical	  gradients	  in	  their	  environment	  and	  bias	  their	  movements	  up	  gradients	  of	  attractant	  and	  down	  gradients	  of	  repellants63.	  Sensing	  of	  chemical	  attractants	  and	  repellants	  in	  E.	  coli	  is	  accomplished	  by	  transmembrane	  receptors	  known	  as	  MCPs.	  MCP	  monomers	  form	  dimers	  and	  the	  dimers	  subsequently	  form	  trimers.	  Trimers-­‐of-­‐dimers	  cluster	  together	  forming	  extended	  hexagonal	  arrays	  consisting	  of	  thousands	  of	  receptors	  with	  one	  trimer-­‐of-­‐dimers	  at	  the	  vertex	  of	  each	  hexagon82,	  87.	  The	  hexagonal	  array	  serves	  as	  a	  platform	  for	  the	  docking	  of	  a	  variety	  of	  chemosensory	  proteins.	  In	  the	  simplest	  core	  array,	  the	  HK	  CheA,	  and	  the	  coupling	  protein	  CheW	  localize	  to	  the	  receptor	  arrays	  at	  the	  cytoplasmic	  tips	  of	  the	  receptors	  and	  maintain	  array	  size80.	  In	  the	  unoccupied,	  apo	  receptor,	  CheA	  kinase	  is	  highly	  active,	  leading	  to	  the	  phorsphorylation	  of	  the	  RR	  CheY.	  Phospho-­‐CheY	  diffuses	  to	  the	  flagella	  where	  it	  biases	  rotation	  of	  the	  flagella.	  Sensing	  of	  chemicals	  in	  periplasmic	  space	  by	  MCPs	  either	  increases	  (repellants)	  or	  decreases	  (attractants)	  CheA	  kinase	  activity62,	  63,	  67.	  Localizing	  the	  receptors,	  CheA,	  and	  CheW	  into	  an	  extended	  array	  confers	  a	  number	  of	  advantages	  including,	  rapid	  signal	  transduction,	  high	  gain	  in	  signal	  amplification,	  and	  high	  cooperativity91,	  92,	  99.	  Previous	  studies	  have	  proposed	  that	  extensive	  interconnectivity	  between	  components	  in	  a	  highly	  ordered	  array	  gives	  rise	  to	  these	  properties,	  and	  recent	  structural	  studies	  have	  helped	  to	  confirm	  this	  hypothesis87,	  99,	  102.	  One	  further	  advantage	  of	  this	  extensive	  interconnectivity	  and	  order	  is	  ultra-­‐stability.	  One	  previous	  study	  has	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proposed	  that	  locking	  all	  of	  the	  interconnected	  parts	  of	  the	  array	  together	  confers	  extra	  stability	  similar	  to	  the	  way	  a	  jig-­‐saw	  puzzle	  gains	  extra	  stability	  once	  all	  of	  its	  pieces	  are	  snapped	  together92.	  	  The	  present	  study	  begins	  by	  characterizing	  the	  decay	  kinetics	  of	  arrays	  in	  vitro	  by	  measuring	  the	  loss	  in	  receptor	  regulated,	  kinase	  activity	  as	  well	  as	  changes	  in	  the	  stoichiometry	  of	  the	  array	  components.	  The	  study	  continues	  by	  characterizing	  the	  molecular	  mechanisms	  underlying	  the	  array	  decay.	  Finally,	  the	  relationship	  between	  array	  order	  and	  stability	  is	  investigated	  by	  introducing	  a	  small	  density	  of	  chemical	  defects	  into	  the	  array	  and	  measuring	  the	  changes	  in	  array	  stability.	  The	  results	  of	  this	  study	  indicate	  that	  arrays	  are	  composed	  of	  two	  stable	  populations	  with	  lifetimes	  of	  days	  and	  weeks	  respectively.	  Moreover,	  there	  is	  a	  strong	  correlation	  between	  array	  order	  and	  stability.	  
Materials	  and	  Methods	  
Materials.	  All	  reagents	  were	  obtained	  from	  Sigma	  Aldrich	  with	  the	  following	  exceptions:	  [γ-­‐32P]ATP	  was	  from	  Perkin-­‐Elmer,	  DTT	  was	  from	  Research	  Products	  International,	  Ni-­‐NTA	  agarose	  resin	  was	  from	  Qiagen,	  Bicinchoninic	  Acid	  Assay	  reagents	  were	  from	  Bio-­‐rad.	  
Protein	  Expression	  and	  Purification.	  Cysless	  CheA	  and	  CheW	  from	  S.	  typhimurium	  were	  expressed	  with	  6xHis	  tags	  on	  their	  N-­‐termini	  from	  the	  plasmids	  pET6H-­‐CheA	  and	  pET6H-­‐CheW	  respectively88.	  CheY	  from	  E.	  coli	  was	  expressed	  with	  an	  N-­‐terminal	  YFP	  and	  C-­‐terminal	  6xHis	  from	  the	  plasmid	  pVSYFP-­‐CheY-­‐6H103.	  All	  soluble	  proteins	  were	  isolated	  as	  previously	  described	  with	  standard	  Ni-­‐NTA	  agarose	  affinity	  chromatography88,	  103.	  Protein	  concentrations	  for	  CheA	  and	  CheW	  were	  estimated	  using	  the	  BCA	  assay	  according	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to	  the	  manufacturer’s	  instructions.	  The	  CheY	  concentration	  was	  estimated	  using	  the	  absorbance	  of	  YFP	  at	  514	  nm	  with	  an	  extinction	  coefficient	  of	  18,000	  M-­‐1cm-­‐1.	  	  	   E.	  coli	  serine	  receptor	  (Tsr)	  was	  overexpressed	  in	  the	  RP3098	  strain	  of	  E.	  coli—which	  lacks	  the	  major	  chemotaxis	  receptors	  and	  their	  associated	  proteins—using	  the	  plasmid	  pJC371.	  Inside	  out,	  inner	  membrane	  vesicles	  containing	  Tsr	  were	  isolated	  as	  previously	  described71.	  The	  total	  protein	  concentration	  in	  the	  membranes	  was	  determined	  with	  the	  BCA	  assay	  and	  the	  fraction	  of	  receptors	  in	  the	  total	  protein	  content	  was	  determined	  by	  quantifying	  SDS-­‐PAGE	  gels	  with	  ImageJ.	  Receptor	  concentration	  was	  estimated	  as	  the	  receptor	  fraction	  in	  the	  total	  protein	  concentration.	  	  	   Reconstitution	  of	  Signaling	  Arrays	  In	  Vitro.	  Signaling	  arrays	  were	  reconstituted	  by	  combining	  6.7	  µM	  Tsr,	  7.5	  µM	  CheA,	  and	  10	  µM	  CheW	  and	  fresh	  PMSF	  (1	  mM)	  in	  activity	  buffer	  (160	  mM	  NaCl,	  5	  mM	  MgCl2,	  50	  mM	  Tris,	  0.5	  mM	  EDTA,	  pH	  7.4)	  for	  one	  hour	  at	  22°C.	  Samples	  were	  centrifuged	  at	  180000g	  for	  6	  minutes	  and	  pellets	  were	  washed	  twice	  by	  resuspending	  in	  a	  ten-­‐fold	  excess	  of	  sample	  buffer	  and	  re-­‐pelleting.	  After	  the	  final	  wash	  pellets	  were	  resuspended	  in	  the	  original	  volume	  of	  activity	  buffer.	  	  	   Array	  Aging	  and	  Exogenous	  Protease	  Conditions.	  Reconstituted	  signaling	  arrays	  were	  stored	  at	  22°C	  in	  an	  insulated	  water	  bath,	  protected	  from	  light.	  CheY	  samples	  were	  stored	  at	  80	  µM	  dilution	  in	  activity	  buffer	  under	  the	  same	  conditions	  for	  up	  to	  five	  days.	  All	  eppendorf	  tubes	  and	  pipet	  tips	  were	  autoclaved	  prior	  to	  use	  and	  aseptic	  technique	  was	  used	  during	  time	  points	  to	  minimize	  the	  chance	  of	  contamination.	  To	  test	  the	  effect	  of	  attractant	  on	  stability	  1	  mM	  serine	  was	  added	  to	  arrays	  during	  reconstitution	  (and	  subsequently	  washed	  out)	  or	  immediately	  after	  reconstitution.	  Exogenous	  protease	  experiments	  were	  carried	  out	  by	  addition	  of	  3	  nM	  trypsin	  immediately	  after	  array	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reconstitution.	  Trypsin	  stocks	  were	  prepared	  fresh	  for	  each	  experiment	  from	  lyophilized	  powder	  and	  dissolved	  in	  1	  mM	  HCl	  at	  pH	  3.	  	  	   Fractional	  Labeling	  of	  Receptors.	  Receptors	  (6.7	  µM)	  resuspended	  in	  activity	  buffer	  with	  fresh	  PMSF	  (1	  mM)	  were	  mixed	  with	  50	  µM	  5-­‐(Iodoacetamido)	  fluorescein	  and	  immediately	  vortexed.	  Aliquots	  of	  receptors	  were	  removed	  every	  ten	  seconds	  and	  quenched	  by	  addition	  of	  80	  mM	  β-­‐mercaptoethanol.	  The	  staggered	  timecourse	  provided	  labeling	  efficiencies	  in	  the	  2-­‐10%	  labeling	  range.	  Labeling	  efficiencies	  were	  determined	  by	  comparison	  to	  a	  denatured,	  100%	  labeled	  control	  on	  SDS	  PAGE	  gels.	  Gels	  were	  imaged	  prior	  to	  and	  after	  coomassie	  staining	  to	  determine	  the	  labeled	  fraction	  of	  receptors	  and	  correct	  for	  changes	  in	  protein	  concentration	  respectively.	  Labeled	  receptors	  were	  reconstituted	  with	  CheA	  and	  CheW	  following	  the	  procedure	  outlined	  for	  standard	  cysless	  components.	  	   Determination	  of	  Attractant	  Regulated	  Kinase	  Activity.	  The	  relative	  kinase	  activity	  of	  arrays	  was	  measured	  as	  previously	  described	  with	  a	  few	  modifications104.	  Five	  microliters	  of	  washed	  and	  resuspended	  arrays	  were	  mixed	  with	  five	  microliters	  of	  YFP-­‐CheY	  yielding	  final	  concentrations	  of	  3.35	  µM	  receptor	  and	  40	  µM	  YFP-­‐CheY.	  Sensitivity	  to	  attractant	  was	  measured	  by	  addition	  of	  1	  mM	  serine.	  	  Under	  these	  conditions	  CheA	  autophosphorylation	  was	  rate	  limiting	  and	  not	  phosphotransfer	  to	  CheY.	  Kinase	  reactions	  were	  carried	  out	  by	  addition	  of	  1	  mM	  [γ-­‐32P]ATP	  (4000-­‐8000	  cpm/pmol)	  followed	  by	  incubation	  for	  10	  seconds.	  Reactions	  were	  quenched	  in	  30	  µL	  of	  2x	  Laemmli	  sample	  buffer	  containing	  50	  mM	  EDTA.	  Samples	  were	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  until	  timecourses	  were	  completed.	  At	  the	  end	  of	  the	  timecourse	  samples	  were	  thawed	  and	  resolved	  on	  denaturing	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SDS	  PAGE	  gels.	  Once	  resolved,	  gels	  were	  extensively	  dried	  and	  then	  imaged	  using	  phosphorimaging.	  	  	  	   Determination	  of	  Changes	  in	  Total	  Protein.	  Changes	  in	  the	  total	  protein	  content	  were	  followed	  by	  removing	  25	  µL	  aliquots	  of	  reconstituted	  arrays,	  pelleting	  the	  arrays	  by	  centrifugation	  at	  180000g	  for	  6	  minutes,	  and	  removing	  the	  supernatant.	  Pellets	  were	  then	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C	  until	  the	  completion	  of	  the	  timecourse.	  Once	  complete,	  pellets	  were	  resuspended	  in	  25	  µL	  of	  2x	  Laemmli	  sample	  buffer,	  boiled,	  resolved	  on	  10%	  SDS	  PAGE	  gels,	  and	  stained	  with	  coomassie	  brilliant	  blue.	  Gels	  were	  imaged	  using	  a	  digital	  camera	  (Alpha	  Innotech)	  and	  relative	  changes	  in	  CheA	  and	  receptor	  were	  determined	  by	  densitometry	  with	  ImageJ	  software.	  Relative	  changes	  in	  CheW	  were	  followed	  by	  western	  blotting	  using	  polyclonal	  antibodies	  against	  CheW	  (a	  gift	  from	  Dr.	  G.	  Hazelbauer).	  The	  proteolysis	  products	  of	  CheA	  were	  similarly	  monitored	  by	  western	  blotting	  using	  a	  polyclonal	  antibody	  against	  CheA	  (a	  gift	  from	  Dr.	  J.	  Stock).	  Briefly,	  dilute	  samples	  were	  resolved	  on	  15%	  or	  10%	  SDS	  PAGE	  gels	  and	  transferred	  to	  PVDF	  membranes.	  Membranes	  were	  blocked	  overnight	  in	  TBST	  with	  3%	  dry	  milk	  powder	  before	  blotting	  with	  anti-­‐CheW	  primary	  and	  anti-­‐rabbit,	  alkaline	  phosphatase	  conjugated	  secondary.	  Extensive	  washing	  with	  TBST	  was	  performed	  after	  incubations.	  Washed	  membranes	  were	  incubated	  with	  ECF	  substrate	  and	  dried	  extensively	  before	  scanning	  with	  a	  Typhoon	  9500	  scanner.	  Blots	  were	  quantified	  by	  densitometry	  using	  ImageJ.	  	  	   	  Measuring	  Changes	  in	  Cooperativity.	  Arrays	  were	  reconstituted	  and	  their	  hill	  coefficient	  was	  immediately	  measured	  by	  mixing	  arrays	  with	  CheY	  and	  increasing	  quantities	  of	  serine	  from	  0.005	  µM	  to	  1000	  µM	  with	  a	  total	  of	  40	  data	  points.	  Samples	  were	  incubated	  with	  serine	  for	  30	  minutes	  to	  ensure	  that	  serine	  was	  able	  to	  diffuse	  inside	  the	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lipid	  vesicles	  to	  the	  serine	  binding	  pocket	  of	  Tsr.	  After	  the	  incubation,	  samples	  were	  immediately	  tested	  for	  kinase	  activity.	  Measurement	  of	  the	  hill	  coefficient	  was	  repeated	  after	  the	  arrays	  were	  aged	  for	  72	  hours	  following	  the	  same	  procedure.	  	  	   Determining	  the	  Symmetry	  of	  CheA	  Proteolysis.	  To	  determine	  the	  symmetry	  of	  CheA	  proteolysis,	  arrays	  were	  formed	  with	  CheA	  E311C,	  a	  mutation	  that	  rapidly	  forms	  disulfide	  crosslinks	  across	  the	  P3	  dimerization	  interface	  of	  two	  CheA	  monomers	  in	  a	  dimer.	  Arrays	  containing	  CheA	  E311C	  were	  formed	  and	  aged	  in	  the	  presence	  of	  3	  mM	  TCEP	  to	  prevent	  damage	  to	  thiols	  and	  also	  prevent	  the	  formation	  of	  crosslinks	  during	  the	  timecourse.	  At	  regular	  intervals,	  10	  µL	  aliquots	  of	  arrays	  were	  removed	  and	  mixed	  with	  90	  µL	  of	  activity	  buffer	  to	  dilute	  the	  TCEP.	  A	  final	  concentration	  of	  6	  mM	  CuCl2	  and	  3	  mM	  EDTA	  was	  added	  to	  catalyze	  the	  disufide	  crosslinking	  reaction.	  Reactions	  were	  allowed	  to	  proceed	  for	  10	  minutes	  before	  arrays	  were	  pelleted	  at	  180000g,	  snap	  frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐80°C	  until	  the	  conclusion	  of	  the	  timecourse.	  Once	  complete	  samples	  were	  resuspended	  in	  2x	  Laemmli	  sample	  buffer,	  diluted,	  and	  resolved	  on	  8%	  SDS	  PAGE	  gels.	  Proteins	  were	  transferred	  to	  PVDF	  membranes	  and	  blotted	  with	  polyclonal	  anti-­‐CheA	  (a	  gift	  from	  Dr.	  J.	  Stock).	  	   Data	  Averaging	  and	  Error	  Analysis.	  All	  data	  points	  shown	  are	  averages	  of	  three	  replicates	  unless	  otherwise	  specified.	  Fit	  parameters	  are	  reported	  as	  an	  average	  of	  at	  least	  three	  replicates	  with	  the	  following	  exceptions:	  for	  the	  exogenous	  trypsin	  data	  (Figure	  5.6,	  Table	  5.2)	  and	  for	  the	  engineered	  defects	  data	  (Figure	  5.9,	  Table	  5.3)	  parameters	  indicate	  a	  single	  measurement	  plus	  or	  minus	  the	  error	  in	  the	  fit.	  Error	  bars	  from	  all	  other	  data	  points	  and	  ranges	  from	  fit	  parameters	  indicate	  the	  standard	  deviation	  unless	  otherwise	  specified.	  
Results	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Experimental	  Strategy.	  	  The	  goals	  of	  this	  study	  are	  to	  investigate	  the	  timescale	  and	  molecular	  mechanism	  of	  the	  remarkable	  ultra-­‐stability	  of	  bacterial	  chemosensory	  arrays.	  	  The	  study	  focuses	  on	  arrays	  formed	  in	  vitro	  from	  the	  three	  core	  components:	  	  receptor,	  CheA	  kinase,	  and	  CheW	  coupling	  protein.	  	  The	  study	  begins	  by	  measuring	  the	  timescale	  of	  array	  stability	  and	  the	  timecourse	  of	  its	  decay.	  CheA	  kinase	  is	  highly	  activated	  in	  the	  intact,	  apo-­‐array.	  	  Thus,	  the	  decay	  timecourse	  is	  measured	  by	  monitoring	  the	  loss	  of	  kinase	  activity	  as	  the	  array	  ages.	  At	  the	  same	  time,	  the	  core	  component	  stoichiometries	  are	  monitored	  to	  detect	  changes	  in	  array	  composition.	  	  By	  directly	  comparing	  the	  timecourse	  of	  changes	  in	  functionality	  and	  composition,	  any	  correlations	  between	  these	  key	  array	  properties	  will	  be	  revealed.	  	  Subsequently,	  the	  study	  investigates	  the	  molecular	  mechanisms	  underlying	  array	  ultra-­‐stability	  by	  probing	  the	  relationships	  between	  array	  order,	  stability,	  and	  cooperativity.	  The	  current	  working	  model	  proposes	  that	  both	  ultra-­‐stability	  and	  receptor-­‐receptor	  cooperativity	  arise	  from	  extensive	  interconnections	  between	  components	  in	  a	  highly	  ordered	  array.	  In	  this	  model,	  regions	  of	  lower	  array	  order	  are	  hypothesized	  to	  exhibit	  lower	  stability,	  less	  steric	  protection	  from	  proteolysis	  and	  lower	  cooperativity.	  	  By	  contrast,	  regions	  of	  higher	  array	  order	  are	  hypothesized	  to	  possess	  greater	  stability	  and	  protection	  from	  proteolysis,	  as	  well	  as	  higher	  cooperativity.	  If	  this	  picture	  is	  valid,	  then	  proteolysis	  should	  degrade	  the	  less-­‐ordered	  regions	  of	  the	  array	  while	  leaving	  the	  well-­‐ordered	  regions	  intact.	  Concomitantly,	  the	  average	  cooperativity	  of	  the	  remaining	  array	  should	  increase	  as	  the	  well-­‐ordered	  regions	  become	  enriched.	  	  Finally,	  to	  more	  directly	  test	  the	  link	  between	  array	  order	  and	  ultra-­‐stability,	  varying	  levels	  of	  engineered	  defects	  are	  introduced	  into	  the	  array	  to	  determine	  the	  level	  of	  order	  required	  for	  ultra-­‐stability.	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Decay	  of	  Kinase	  Activity	  as	  the	  Array	  Ages.	  The	  array	  decay	  timecourse	  of	  Tsr	  inner	  membrane	  arrays	  reconsituted	  with	  CheA	  and	  CheW	  in	  vitro	  were	  quantitated	  by	  kinase	  activity	  measurements.	  Figure	  5.1	  displays	  a	  representative	  20-­‐day	  timecourse.	  	  Approximately	  50%	  of	  the	  initial	  kinase	  activity	  decays	  during	  the	  first	  1-­‐2	  days,	  but	  the	  remaining	  kinase	  activity	  is	  truly	  ultra-­‐stable	  and	  decays	  very	  slowly	  over	  the	  remaining	  20	  days	  (Figure	  5.1).	  	  
	  
Figure	  5.1:	  Kinase	  activity	  as	  array	  ages.	  Tsr	  inner	  membrane	  arrays	  reconstituted	  in	  vitro	  with	  cysless,	  his-­‐tagged	  CheA	  and	  CheW	  were	  incubated	  at	  22°C	  for	  20	  days.	  Each	  day	  of	  the	  timecourse	  a	  sample	  of	  the	  arrays	  was	  removed	  and	  mixed	  with	  CheY	  and	  ATP	  to	  determine	  the	  kinase	  activity	  of	  the	  array	  ().	  Another	  sample	  was	  mixed	  with	  serine	  to	  determine	  if	  the	  kinase	  activity	  was	  attractant	  regulated	  ().	  All	  kinase	  activities	  were	  normalized	  to	  the	  initial	  activity.	  	  	  Impressively,	  the	  arrays	  are	  fully	  regulated	  by	  the	  attractant	  serine	  throughout	  this	  20	  day	  period.	  The	  effect	  of	  serine	  on	  array	  assembly	  and	  array	  stability	  was	  tested	  in	  a	  5	  day	  timecourse	  (Figure	  A.1).	  No	  significant	  changes	  in	  the	  decay	  kinetics	  were	  observed	  in	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either	  case.	  Nonlinear	  least	  squares,	  best-­‐fit	  analysis	  reveals	  the	  timecourse	  is	  well-­‐described	  by	  a	  two-­‐component	  model	  consisting	  of	  two	  decaying	  exponential	  terms:	  f(x)	  	  =	  	  Af	  e–t/τf	  	  +	  As	  e–t/τs	  	   	   	   	   	   	   	   	   (Eq.	  1)	  where	  Af	  and	  As	  are	  the	  amplitudes	  of	  the	  fast-­‐decaying	  and	  slow-­‐decaying	  components,	  respectively,	  and	  τf	  and	  τs	  are	  the	  time	  constants	  of	  the	  fast-­‐decaying	  and	  slow	  decaying	  components,	  respectively.	  Hereafter,	  these	  components	  will	  be	  referred	  to	  as	  quasi-­‐stable	  and	  ultra-­‐stable	  components,	  respectively.	  Comparison	  of	  different	  best-­‐fit	  models	  indicates	  these	  two-­‐component	  fits	  are	  adequate,	  since	  additional	  exponential	  terms	  are	  not	  statistically	  justified.	  Averaging	  the	  best	  fit	  parameters	  from	  four	  different	  timecourses	  reveals	  that	  51	  +	  3%	  of	  the	  array	  exhibits	  a	  mean	  kinase	  lifetime	  of	  29	  +	  9	  hours	  while	  49	  +	  2%	  of	  the	  array	  is	  ultra-­‐stable	  with	  a	  mean	  kinase	  lifetime	  of	  457	  +	  58	  hours	  (Table	  5.1).	  The	  best	  fit	  parameters	  observed	  in	  this	  experiment	  were	  not	  significantly	  different	  than	  the	  parameters	  for	  the	  decay	  of	  full-­‐length	  CheA.	  The	  decay	  observed	  in	  these	  experiments	  was	  not	  due	  to	  microbial	  contamination	  as	  no	  microbial	  growth	  was	  present	  in	  the	  sample	  tubes	  throughout	  the	  timecourse.	  Addition	  of	  0.01%	  azide	  to	  samples	  did	  not	  alter	  the	  decay	  kinetics	  or	  lifetime.	  
	  
Table 5.1: Summary of Two Component Fit Parameters!
Components! f(x) = Afe-x/!f + Ase-x/!s !
!f! Af! !s! As!
Kinase 
Activity!




24 ± 5 ! 0.52 ± 0.1 ! 463 ± 38 ! 0.48 ± 0.1 !
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Determining	  the	  Mechanism	  of	  Kinase	  Activity	  Loss	  During	  Array	  Aging.	  The	  initial	  decay	  of	  kinase	  activity	  following	  array	  assembly	  could	  arise	  from	  kinase	  dissociation,	  since	  the	  free	  kinase	  is	  over	  100-­‐fold	  less	  active.	  	  Alternatively,	  the	  kinase	  could	  remain	  in	  the	  array	  but	  be	  inactivated	  by	  alteration	  of	  the	  kinase	  molecule.	  	  To	  distinguish	  these	  possibilities,	  the	  protein	  composition	  of	  the	  array	  was	  monitored	  more	  closely	  in	  parallel	  with	  kinase	  activity.	  Throughout	  the	  timecourse,	  identical	  aliquots	  of	  arrays	  were	  a)	  subjected	  to	  kinase	  assays	  and	  b)	  centrifuged	  at	  high	  speed	  to	  separate	  array	  pellets	  from	  unbound	  components.	  	  Array	  pellets	  were	  analyzed	  by	  SDS-­‐PAGE	  gels	  to	  quantitate	  their	  core	  components.	  	  
	  
Figure	  5.2:	  Comparing	  the	  kinetics	  of	  kinase	  activity	  and	  protein	  loss.	  Tsr	  inner	  membrane	  arrays	  were	  reconstituted	  in	  vitro	  and	  incubated	  at	  22°C	  for	  20	  days.	  Each	  day	  of	  the	  timecourse	  a	  sample	  of	  the	  arrays	  was	  removed	  and	  mixed	  with	  CheY	  and	  ATP	  to	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determine	  the	  kinase	  activity	  of	  the	  array	  ().	  Another	  sample	  was	  pelleted	  to	  separate	  array	  bound	  CheA()	  from	  CheA	  in	  the	  supernate	  ().	  Pelleted	  samples	  were	  also	  utilized	  to	  determine	  the	  relative	  quantity	  of	  array	  bound,	  full-­‐length	  CheW	  ()	  and	  full-­‐length	  Tsr	  ().	  All	  kinase	  activities	  and	  full-­‐length	  protein	  contents	  were	  normalized	  to	  their	  initial	  values.	  	  	   Figure	  5.2	  summarizes	  the	  relative	  levels	  of	  receptor,	  CheW	  and	  CheA	  during	  a	  representative	  20	  day	  timecourse.	  The	  total	  levels	  of	  Tsr	  and	  CheW	  both	  decay	  slowly	  following	  a	  single	  exponential	  decay	  yielding	  relative	  full-­‐length	  protein	  losses	  of	  40%	  and	  68%	  respectively	  over	  the	  timecourse.	  By	  far	  the	  largest	  change	  is	  observed	  for	  CheA:	  the	  level	  of	  full-­‐length	  CheA	  begins	  to	  drop	  after	  array	  formation	  and	  its	  loss	  is	  closely	  correlated	  to	  the	  loss	  of	  kinase	  activity,	  reaching	  approximately	  an	  11%	  level	  of	  full-­‐length	  protein	  during	  the	  20	  day	  incubation.	  Relative	  loss	  of	  full-­‐length	  CheA	  is	  best	  fit	  by	  a	  sum	  of	  two	  single	  exponential	  decays	  (Equation	  1)	  and	  the	  best	  fit	  parameters	  are	  not	  statistically	  different	  from	  the	  kinase	  activity	  decay	  parameters	  (Table	  5.1).	  To	  test	  the	  correlation,	  between	  loss	  of	  CheA	  and	  loss	  of	  kinase	  activity,	  Figure	  5.3	  plots	  the	  relative	  level	  of	  full-­‐length,	  array-­‐bound	  CheA	  against	  relative	  kinase	  activity,	  as	  determined	  for	  the	  large	  number	  of	  time	  points	  in	  the	  decay	  timecourses.	  Least-­‐squares	  best	  fit	  analysis	  confirms	  the	  correlation	  is	  highly	  linear	  (slope	  of	  0.98	  ±	  0.06,	  R	  =	  0.988),	  suggesting	  that	  the	  kinase	  activity	  loss	  may	  arise	  from	  the	  decreasing	  level	  of	  full-­‐length	  CheA	  with	  time.	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Figure	  5.3:	  Examining	  the	  molecular	  basis	  of	  activity	  loss.	  Tsr	  inner	  membrane	  arrays	  were	  reconstituted	  in	  vitro	  and	  incubated	  at	  22°C	  for	  20	  days.	  Each	  day	  of	  the	  timecourse	  a	  sample	  of	  the	  arrays	  was	  removed	  and	  mixed	  with	  CheY	  and	  ATP	  to	  determine	  the	  kinase	  activity	  of	  the	  array.	  Another	  sample	  was	  pelleted	  to	  separate	  array	  bound	  CheA	  from	  CheA	  in	  the	  supernate.	  Relative	  losses	  in	  kinase	  activity	  were	  plotted	  against	  relative	  losses	  in	  full-­‐length	  CheA	  in	  four	  different	  timecourses.	  	  	  	   The	  depletion	  of	  full-­‐length	  CheA	  in	  arrays	  was	  further	  examined	  to	  ascertain	  whether	  the	  loss	  arose	  from	  in-­‐situ	  proteolysis	  or	  dissociation	  from	  the	  array.	  Examination	  of	  the	  supernatant	  from	  array	  pellets	  indicates	  that	  no	  detectable	  quantity	  of	  full-­‐length	  CheA	  dissociates	  from	  the	  array	  over	  the	  duration	  of	  the	  timecourse	  (Figure	  5.2).	  Instead,	  western	  blot	  analysis	  of	  array	  pellets	  with	  polyclonal	  anti-­‐CheA	  antibody	  reveals	  that	  two	  CheA	  proteolysis	  fragments	  build	  up	  in	  the	  array	  on	  the	  same	  timescale	  as	  the	  loss	  of	  full	  length	  CheA,	  as	  illustrated	  in	  Figure	  5.4A,B.	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observed	  throughout	  the	  first	  5	  days	  of	  array	  aging,	  suggesting	  that	  the	  proteolyzed	  CheA	  fragments	  remain	  bound	  to	  the	  array	  over	  this	  timescale.	  After	  5	  days,	  the	  sum	  of	  the	  CheA	  fragments	  begins	  to	  slowly	  decay	  reaching	  a	  final	  level	  of	  41%	  of	  initial	  CheA.	  During	  this	  second	  phase	  of	  decay	  the	  CheA	  fragments	  are	  further	  proteolyzed	  and	  completely	  decay	  by	  the	  end	  of	  the	  timecourse.	  Fitting	  the	  sum	  of	  full-­‐length	  CheA	  and	  fragments	  requires	  both	  a	  linear	  component	  for	  the	  first	  five	  days	  and	  a	  single	  exponential	  decay	  component	  for	  the	  remaining	  five	  days.	  The	  linear	  fit	  over	  the	  first	  five	  days	  confirms	  that	  during	  the	  5	  day	  timecourse	  very	  little	  CheA	  dissociates	  from	  the	  array.	  One	  explanation	  for	  these	  results	  is	  that	  full-­‐length	  CheA	  gets	  proteolyzed	  at	  the	  long,	  flexible	  linkers	  joining	  P1-­‐P2	  or	  P2-­‐P3,	  yielding	  previously	  described	  fragments	  of	  CheA105.	  The	  larger	  P2-­‐P3-­‐P4-­‐P5	  and	  P3-­‐P4-­‐P5	  fragments	  retain	  the	  core	  P3-­‐P4-­‐P5	  region	  and	  remain	  stably	  bound	  in	  the	  array	  while	  the	  smaller	  P1	  and	  P1-­‐P2	  fragments	  dissociate	  from	  the	  array.	  The	  exponential	  fit	  over	  the	  remaining	  16	  days	  of	  the	  timecourse	  suggests	  that	  both	  full-­‐length	  CheA	  and	  the	  fragments	  are	  being	  proteolyzed,	  although	  we	  cannot	  determine	  if	  these	  molecules	  are	  proteolyzed	  in	  the	  array	  or	  immediately	  after	  dissociation	  from	  the	  array.	  The	  time	  constant	  for	  the	  exponential	  decay	  component	  reveals	  that	  the	  sum	  of	  CheA	  and	  its	  fragments	  has	  an	  average	  lifetime	  (516	  ±	  72	  hours)	  that	  is	  within	  error	  of	  the	  kinase	  activity	  lifetime	  (457	  ±	  53	  hours),	  suggesting	  that	  these	  two	  variables	  decay	  at	  a	  similar	  rate.	  Collectively,	  these	  experiments	  are	  consistent	  with	  the	  previous	  observation	  that	  once	  CheA	  and	  CheW	  are	  stably	  integrated	  into	  the	  array	  there	  is	  no	  observable	  exchange	  of	  array-­‐bound	  CheA	  with	  free	  CheA	  in	  solution92.	  
Addition	  of	  Exogenous	  Protease	  to	  Test	  for	  Steric	  Protection	  by	  the	  Array.	  The	  rapid	  proteolysis	  of	  half	  of	  the	  CheA	  subunits	  followed	  by	  the	  slow	  proteolysis	  of	  the	  remaining	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half	  may	  originate	  from	  mosaic	  organization	  of	  quasi-­‐	  and	  ultra-­‐stable	  regions	  of	  array.	  Another	  possibility	  is	  the	  asymmetric	  degradation	  of	  CheA	  dimers	  such	  that	  the	  entire	  dimer	  population	  has	  one	  intact	  and	  one	  proteolyzed	  subunit.	  To	  address	  the	  model	  of	  steric	  protection,	  a	  small	  quantity	  of	  trypsin	  (3	  nM)	  was	  added	  to	  Tsr	  inner	  membrane	  arrays	  immediately	  after	  array	  formation	  and	  the	  relative	  kinase	  activity	  of	  the	  arrays	  were	  tracked	  over	  a	  5	  day	  timecourse.	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   Addition	  of	  3	  nM	  trypsin	  caused	  a	  rapid	  decrease	  in	  kinase	  activity.	  (Figure	  5.5).	  Strikingly,	  after	  this	  rapid	  decrease,	  the	  remaining	  kinase	  activity	  was	  relatively	  constant	  over	  the	  remaining	  five	  days	  of	  the	  experiment.	  For	  the	  shorter	  five	  day	  timecourse	  under	  standard	  conditions,	  a	  variation	  of	  Eq.	  1	  with	  both	  time	  constants	  set	  to	  the	  predetermined	  averages	  was	  utilized	  to	  model	  the	  data	  (Eq.	  2)	  f(x)	  	  =	  	  Af	  e–t/τf	  	  +	  As	  e–t/τs	  :	  where	  τf	  =	  29	  and	  τs	  =	  457	   	   	   	   (Eq.	  2)	  The	  two	  component	  exponential	  decay	  model	  proved	  insufficient	  to	  fit	  the	  trypsinized	  data.	  A	  three	  component	  model	  consisting	  of	  three	  exponential	  decays	  provided	  a	  better	  fit:	  f(x)	  	  =	  Avf	  e–t/τvf	  +	  Af	  e–t/τf	  	  +	  As	  e–t/τs	  :	  where	  τf	  =	  29	  and	  τs	  =	  457	   	   	   	   (Eq.	  2)	  This	  model	  confirms	  that	  the	  mean	  lifetime	  for	  32	  ±	  6%	  of	  the	  array	  is	  just	  0.7	  ±	  0.4	  hours.	  	  Roughly	  19	  ±	  6%	  of	  the	  arrays	  are	  quasi-­‐stable	  and	  the	  remaining	  48	  ±	  6%	  are	  ultra-­‐stable	  and	  experience	  little	  or	  no	  decay	  over	  this	  timecourse	  (Table	  5.2).	  Throughout	  the	  entire	  timecourse	  arrays	  retain	  sensitivity	  to	  attractant.	  
	  	   To	  determine	  if	  proteolysis	  is	  causing	  asymmetric	  degradation	  of	  all	  CheA	  dimers	  or	  symmetric	  degradation	  of	  half	  the	  dimers,	  CheA	  subunits	  with	  a	  single	  cysteine	  mutation	  at	  position	  E311C	  were	  disulfide	  cross-­‐linked	  to	  one	  another	  prior	  to	  denaturing	  and	  gel	  
Table 5.2: Summary of Three Component Fit Parameters !
for Arrays With Exogenous Trypsin!
f(x) = Avfe-x/!vf + Afe-x/!f +  Ase-x/!s !
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electrophoresis.	  Cross-­‐linking	  CheA	  dimers	  reveals	  that	  the	  majority	  of	  full-­‐length	  CheA	  subunits	  are	  part	  of	  a	  symmetric	  dimer	  where	  both	  CheA	  subunits	  are	  full-­‐length	  (Figure	  5.6A).	  The	  major	  cross-­‐linking	  product	  is	  consistently	  full-­‐length	  CheA	  homodimers	  over	  a	  5	  day	  timecourse.	  Several	  larger	  degradation	  bands	  of	  CheA	  are	  also	  cross-­‐linked.	  However,	  these	  bands	  are	  relatively	  minor	  compared	  to	  the	  full-­‐length	  dimer.	  Unfortunately	  these	  bands	  could	  not	  be	  assigned	  to	  known	  degradation	  products	  of	  CheA.	  The	  inability	  to	  assign	  the	  bands	  is	  not	  unexpected	  as	  disulfide	  bonds	  often	  cause	  proteins	  to	  run	  at	  erroneous	  molecular	  weights	  on	  SDS	  gels.	  	  Quantifying	  the	  density	  of	  the	  CheA	  dimer	  band	  over	  the	  5	  day	  timecourse	  yields	  a	  decay	  profile	  that	  is	  strikingly	  similar	  to	  the	  kinase	  activity	  decay	  profile	  of	  Cysless	  arrays	  (Figure	  5.6B).	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The	  rapid	  decrease	  in	  kinase	  activity	  with	  3	  nM	  trypsin	  and	  the	  symmetric	  degradation	  of	  CheA	  suggests	  that	  ultra-­‐stable	  arrays	  are	  protected	  from	  proteolysis	  while	  quasi-­‐stable	  the	  arrays	  are	  not.	  	  
Relationship	  Between	  Order	  and	  Cooperativity	  in	  the	  Array.	  The	  differences	  observed	  in	  array	  stability	  and	  the	  steric	  protection	  of	  some	  CheA	  dimers	  from	  proteolysis	  may	  arise	  from	  differences	  in	  the	  degree	  of	  order	  in	  different	  regions	  of	  the	  array.	  In	  this	  model,	  ultra-­‐stable	  regions	  are	  highly	  ordered	  and	  sterically	  protected	  from	  proteolysis	  while	  quasi-­‐stable	  regions	  are	  less	  ordered	  and	  less	  resistant	  to	  proteolysis.	  To	  test	  this	  model,	  the	  cooperativity	  of	  arrays	  was	  measured	  immediately	  after	  complex	  formation	  and	  after	  several	  days	  of	  aging	  when	  the	  less	  stable	  components	  were	  degraded.	  Tsr	  inner	  membrane	  arrays	  were	  formed	  and	  titrated	  with	  increasing	  amounts	  of	  serine	  to	  determine	  their	  Hill	  coefficients.	  	  Measurements	  were	  completed	  about	  1	  hour	  after	  array	  formation	  and	  72	  hours	  after	  array	  formation.	  Data	  from	  these	  experiments	  were	  fit	  to	  a	  model	  of	  the	  Hill	  equation	  derived	  by	  Bornhorst	  and	  Falke91.	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Figure	  5.7:	  Relationship	  between	  order	  and	  cooperativity	  in	  arrays.	  Tsr	  inner	  membrane	  arrays	  were	  reconstituted	  in	  vitro	  and	  incubated	  under	  standard	  conditions	  for	  five	  days	  at	  22°C.	  	  On	  the	  initial	  day	  ()	  and	  third	  day	  ()	  of	  the	  timecourse	  aliquots	  of	  the	  arrays	  were	  mixed	  with	  CheY,	  ATP,	  and	  serine	  (0.005-­‐1000	  µM).	  Kinase	  activities	  of	  samples	  are	  plotted	  relative	  to	  a	  serine	  free	  control	  sample.	  	  	  	   In	  three	  different	  trials,	  the	  average	  hill	  coefficient	  of	  Tsr	  inner	  membrane	  arrays	  immediately	  after	  formation	  was	  1.4	  ±	  0.2	  with	  a	  K1/2	  of	  25	  ±	  7	  µM	  (Figure	  5.7).	  After	  three	  days	  of	  incubation,	  resulting	  in	  the	  degradation	  of	  the	  less	  stable	  array	  populations,	  the	  average	  hill	  coefficient	  increased	  to	  2.5	  ±	  0.5	  with	  a	  K1/2	  of	  95	  ±	  9	  µM.	  The	  nearly	  two	  fold	  increase	  in	  cooperativity	  suggests	  that	  the	  ultra-­‐stable	  and	  sterically	  protected	  sections	  of	  array	  have	  higher	  order	  than	  the	  quasi-­‐stable	  sections	  of	  array.	  The	  increase	  in	  K1/2	  is	  consistent	  with	  previous	  observations	  that	  K1/2	  increases	  as	  the	  cooperativity	  of	  arrays	  increases75,	  91.	  The	  observation	  of	  cooperative	  differences	  between	  quasi-­‐stable	  and	  ultra-­‐stable	  regions	  is	  consistent	  with	  modeling	  studies	  that	  have	  proposed	  neighborhoods	  of	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>20	  receptor	  dimers	  can	  couple	  strongly	  together	  and	  signal	  as	  a	  single	  unit102.	  Cryo-­‐EM	  studies	  have	  also	  shown	  the	  presence	  of	  densely	  packed	  and	  loosely	  packed	  sections	  of	  array106,107.	  
Examining	  the	  Effects	  of	  Engineered	  Defects	  on	  Array	  Stability.	  To	  further	  examine	  the	  relationship	  between	  array	  stability	  and	  order,	  a	  small	  density	  of	  engineered	  defects	  were	  introduced	  into	  the	  array	  before	  aging.	  A	  single	  cysteine	  mutant	  (V398C)	  was	  introduced	  into	  the	  natively	  cysless	  Tsr	  and	  co-­‐expressed	  in	  a	  roughly	  1:1	  ratio	  with	  wild-­‐type	  Tsr	  to	  minimize	  formation	  of	  inter-­‐receptor	  disulfide	  bonds.	  The	  V398C	  mutant	  is	  natively	  non-­‐perturbing	  with	  wild-­‐type	  kinase	  activity	  and	  CheA/CheW	  incorporation	  in	  array	  formation.	  However,	  completely	  labeling	  this	  position	  with	  a	  bulky	  fluorescein	  probe	  abolishes	  kinase	  activity	  and	  array	  assembly,	  thus	  providing	  a	  convenient	  way	  for	  introducing	  an	  adjustable	  density	  of	  defects	  into	  the	  array108.	  A	  population	  of	  the	  position	  398	  cysteines	  (2%-­‐50%	  of	  total	  receptors)	  was	  labeled	  with	  a	  fluorescein	  probe	  to	  create	  different	  densities	  of	  defects	  in	  the	  array.	  Labeled	  arrays	  were	  reconstituted	  with	  CheA	  and	  CheW	  and	  the	  arrays	  were	  allowed	  to	  age.	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Figure	  5.8:	  Examining	  the	  relationship	  between	  defects	  and	  stability.	  Tsr	  receptor	  arrays	  were	  fractionally	  labeled	  with	  5-­‐IAF	  to	  simulate	  defects	  in	  the	  array.	  Once	  labeled,	  the	  receptor	  arrays	  were	  reconstituted	  with	  CheA	  and	  CheW	  in	  vitro	  and	  incubated	  under	  standard	  conditions	  for	  five	  days	  at	  22°C.	  Arrays	  were	  formed	  with	  wild-­‐type	  (),	  unlabeled	  V398C	  receptor	  (),	  2%	  labeled	  V398C	  (),	  6%	  labeled	  V398C	  (),	  and	  50%	  labeled	  V398C	  ().	  Each	  day	  of	  the	  timecourse	  samples	  of	  the	  array	  were	  mixed	  with	  ATP	  and	  CheY	  to	  test	  the	  kinase	  activity	  of	  the	  arrays.	  Attractant	  regulation	  was	  tested	  on	  the	  initial,	  second,	  and	  fifth	  day	  of	  the	  experiment	  by	  addition	  of	  1	  mM	  serine	  (open	  symbols).	  	  	   Figure	  5.8	  shows	  a	  kinase	  activity	  decay	  profile	  for	  0%,	  2%,	  6%,	  and	  50%	  labeled	  receptors.	  The	  0%	  labeled	  V398C	  arrays	  have	  nearly	  indistinguishable	  kinase	  activity	  decay	  from	  wild-­‐type	  Tsr,	  indicating	  that	  the	  chosen	  mutant	  is	  not	  a	  source	  of	  defects	  in	  itself.	  Labeling	  just	  2%	  of	  the	  cysteines	  causes	  kinase	  activity	  to	  slowly	  decay	  to	  almost	  zero	  by	  the	  fifth	  day.	  Doubling	  the	  density	  of	  defect	  to	  6%	  leads	  to	  an	  even	  faster	  decay	  and	  increasing	  the	  density	  to	  50%	  leads	  to	  a	  total	  loss	  in	  activity	  after	  2	  days.	  Fitting	  these	  data	  with	  Equation	  2	  confirms	  these	  qualitative	  observations.	  Pure	  wild-­‐type	  Tsr	  or	  the	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V398C/wild-­‐type	  Tsr	  mixed	  arrays	  have	  a	  slowly	  degrading	  component	  consisting	  of	  42	  ±	  6%	  of	  the	  array	  with	  a	  mean	  lifetime	  of	  46	  ±	  9	  hours	  and	  an	  ultra-­‐stable	  component	  encompassing	  53	  ±	  6%	  of	  the	  array	  (Table	  5.3).	  Labeling	  2%	  of	  the	  postion	  398	  cysteines	  causes	  91	  ±	  7%	  of	  the	  lattice	  to	  have	  a	  mean	  kinase	  lifetime	  of	  47	  ±	  8	  hours	  and	  the	  ultra-­‐stable	  component	  is	  negligible	  (4	  ±	  7%).	  Additional	  labeling	  does	  not	  cause	  the	  less	  stable	  component	  of	  the	  arrays	  to	  increase	  in	  size	  significantly.	  However,	  the	  mean	  kinase	  lifetime	  of	  the	  less	  stable	  component	  decreases	  to	  23	  ±	  3	  hours	  with	  6%	  labeling	  and	  5	  ±	  2	  hours	  with	  50%	  labeling.	  The	  conversion	  of	  nearly	  all	  of	  the	  ultra-­‐stable	  arrays	  into	  a	  less	  stable	  array	  with	  just	  a	  small	  density	  of	  defects	  (2%)	  suggests	  that	  the	  differences	  between	  these	  two	  arrays	  are	  minor.	  Collectively,	  the	  observations	  in	  this	  experiment	  support	  a	  model	  in	  which	  a	  low	  density	  of	  packing	  defects	  in	  a	  highly	  ordered	  array	  is	  necessary	  for	  ultra-­‐stability.	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   Given	  the	  observation	  that	  chemosensory	  arrays	  are	  highly	  sensitive	  to	  defects,	  the	  effect	  of	  increasing	  levels	  of	  fluorescein	  labeling	  on	  initial	  kinase	  activity	  and	  CheA	  incorporation	  was	  also	  examined.	  A	  roughly	  linear	  decrease	  in	  kinase	  activity	  and	  CheA	  incorporation	  was	  observed	  as	  labeling	  increased	  from	  0%	  up	  to	  6%	  (Figure	  5.9).	  The	  slope	  of	  the	  linear	  fit	  indicates	  that	  just	  1%	  of	  labeling	  causes	  an	  8	  ±	  1%	  decrease	  in	  kinase	  activity	  and	  CheA	  incorporation.	  	  These	  results	  indicate	  that	  assembly	  of	  the	  array	  is	  cooperative	  and	  even	  a	  small	  defect	  can	  prevent	  a	  number	  of	  CheA	  molecules	  from	  integrating	  into	  the	  array.	  Moreover,	  these	  results	  further	  reinforce	  the	  idea	  that	  ultra-­‐stable	  arrays	  require	  a	  very	  low	  density	  of	  defects.	  
Table 5.3: Summary of Two Component Fit Parameters!
 for Fractionally Labeled V398C Arrays!
f(x) = Ae-x/! +  c!
Receptor! Label Density (%)! ! (A)! c!
Tsr-WT! 0! 46 ± 9 (0.42 ± 0.06)  ! 0.53 ± 0.06 !
Tsr-V398C/WT! 0! 42 ± 11 (0.41 ± 0.06) ! 0.54 ± 0.05!
Tsr-V398C/WT! 2 ± 0.3! 47 ± 8 (0.91 ± 0.07) ! 0.04 ± 0.07!
Tsr-V398C/WT! 6 ± 0.2! 23 ± 3 (0.91 ± 0.02) ! 0.06 ± 0.09!
Tsr-V398C/WT! 50 ± 2! 5 ± 2 (0.96 ± 0.06) ! 0.03 ± 0.03!
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Figure	  5.9:	  Effect	  of	  engineered	  defects	  on	  assembly.	  Tsr	  receptor	  arrays	  were	  fractionally	  labeled	  with	  5-­‐IAF	  to	  simulate	  defects	  in	  the	  array.	  Once	  labeled,	  the	  receptor	  arrays	  were	  reconstituted	  with	  CheA	  and	  CheW	  in	  vitro	  and	  their	  immediate	  kinase	  activity	  ()	  and	  CheA	  incorporation	  ()	  were	  measured.	  
	  
Discussion	  	  
Arrays	  Consist	  of	  Two	  Stable	  Populations.	  The	  results	  presented	  here	  demonstrate	  that	  arrays	  are	  composed	  of	  two	  equally	  sized,	  stable	  populations:	  a	  quasi-­‐stable	  population	  with	  a	  lifetime	  of	  29	  ±	  9	  hours	  and	  an	  ultra-­‐stable	  population	  with	  an	  average	  lifetime	  of	  457	  ±	  53	  hours.	  The	  observation	  that	  these	  populations	  and	  their	  kinetics	  are	  unaltered	  by	  the	  attractant	  serine	  during	  array	  formation	  or	  array	  aging	  is	  consistent	  with	  previous	  results	  showing	  that	  changes	  in	  receptor	  conformation	  during	  on/off	  switching	  in	  the	  array	  are	  small87,	  94,	  109.	  Collectively,	  these	  observations	  provide	  further	  support	  for	  the	  view	  that	  the	  structural	  changes	  associated	  with	  ligand	  binding	  are	  small	  and	  do	  no	  change	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the	  overall	  stability	  of	  the	  complex.	  This	  could	  be	  advantageous	  as	  these	  arrays	  are	  constantly	  must	  be	  able	  to	  rapidly	  switch	  on	  and	  off	  and	  also	  switch	  from	  highly	  kinase	  active	  (QQQQ)	  to	  less	  kinase	  active	  (EEEE)	  methylation	  states.	  If	  arrays	  quickly	  degraded	  in	  the	  on	  or	  off	  state	  this	  would	  present	  a	  significant	  challenge	  to	  bacteria.	  	  
Proteolysis	  of	  Full-­length	  CheA	  is	  Responsible	  for	  the	  Loss	  in	  Kinase	  Activity.	  Loss	  of	  kinase	  activity	  in	  the	  quasi-­‐	  and	  ultra-­‐stable	  populations	  originates	  from	  the	  decay	  of	  full-­‐length	  CheA	  in	  arrays.	  Decay	  of	  kinase	  activity	  is	  highly	  correlated	  with	  the	  decay	  of	  full-­‐length	  CheA,	  but	  not	  correlated	  to	  decay	  of	  either	  receptors	  or	  CheW.	  While	  the	  observation	  that	  loss	  of	  CheA	  kinase	  is	  highly	  correlated	  with	  loss	  of	  kinase	  activity	  is	  not	  surprising,	  this	  result	  has	  further	  implications.	  Phosphotransfer	  in	  array	  bound	  CheA	  is	  100	  fold	  faster	  than	  free	  CheA110.	  Perturbation	  of	  some	  of	  these	  CheA-­‐receptor	  or	  CheA-­‐CheW	  contacts	  could	  lower	  kinase	  activity	  without	  any	  physical	  degradation	  of	  CheA	  itself.	  The	  results	  presented	  here	  rule	  out	  this	  scenario	  and	  also	  suggest	  that	  the	  interactions	  between	  CheA,	  CheW,	  and	  receptor	  are	  not	  significantly	  altered	  throughout	  the	  aging	  process.	  	  	  The	  decay	  of	  full-­‐length	  CheA	  is	  concurrent	  with	  the	  build	  up	  of	  two	  known	  proteolysis	  fragments	  of	  CheA	  at	  the	  flexible	  linkers	  between	  the	  P1-­‐P2	  and	  P2-­‐P3	  domains	  of	  CheA105.	  The	  observation	  that	  these	  CheA	  fragments	  remain	  stably	  intergrated	  into	  the	  array	  is	  not	  surprising	  as	  all	  of	  the	  important	  CheA	  interactions	  with	  receptor	  and	  CheW	  are	  located	  in	  the	  P3-­‐P4-­‐P5	  domains	  of	  CheA88.	  Impressively,	  adding	  up	  the	  total	  density	  of	  the	  degradation	  bands	  along	  with	  the	  remaining	  full-­‐length	  CheA	  density	  at	  a	  given	  time	  point	  yields	  a	  sum	  which	  is	  nearly	  equivalent	  to	  the	  starting	  density	  of	  full-­‐length	  CheA.	  This	  relationship	  holds	  for	  about	  5	  days	  after	  which	  the	  degradation	  bands	  are	  gradually	  lost	  from	  the	  array	  and	  the	  sum	  of	  full-­‐length	  CheA	  and	  its	  fragments	  decays	  at	  a	  rate	  that	  is	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indistinguishable	  from	  the	  decay	  of	  kinase	  activity.	  Collectively	  these	  results	  indicate	  that	  the	  ultra-­‐stable	  arrays	  are	  not	  significantly	  proteolyzed	  throughout	  the	  initial	  five	  days	  of	  the	  timecourse.	  Only	  after	  five	  days	  of	  aging	  do	  the	  ultra-­‐stable	  arrays	  begin	  to	  be	  proteolyzed.	  	  Throughout	  the	  timecourse,	  no	  significant	  quantities	  of	  CheA	  or	  its	  fragments	  are	  detected	  in	  the	  supernatant.	  The	  lack	  of	  CheA	  fragments	  building	  up	  in	  the	  supernatant	  and	  the	  observation	  that	  the	  P3-­‐P4-­‐P5	  core	  of	  CheA	  remains	  stably	  integrated	  into	  the	  array	  suggests	  that	  proteolysis	  and	  not	  dissociation	  of	  CheA	  is	  the	  driving	  force	  behind	  array	  decay.	  Admittedly,	  CheA	  that	  dissociates	  from	  the	  array	  could	  be	  rapidly	  degraded	  and	  may	  not	  be	  observable	  on	  an	  SDS	  gel.	  However,	  given	  the	  presence	  of	  the	  degradation	  bands	  over	  the	  first	  five	  days,	  it	  is	  reasonable	  to	  assume	  that	  dissociation	  of	  CheA	  only	  plays	  a	  minor	  role,	  if	  any,	  in	  array	  decay.	  	  One	  explanation	  for	  these	  observations	  is	  that	  CheA	  subunits	  in	  the	  quasi-­‐stable	  population	  are	  more	  susceptible	  to	  proteolysis	  than	  CheA	  subunits	  in	  the	  ultra-­‐stable	  population.	  One	  mechanism	  for	  this	  proteolytic	  protection	  is	  that	  CheA	  subunits	  in	  ultra-­‐stable	  arrays	  are	  sterically	  protected	  from	  proteolysis.	  One	  previous	  study	  has	  shown	  that	  the	  flexible	  linkers	  between	  the	  P1-­‐P2	  and	  P2-­‐P3	  are	  constrained	  as	  CheA	  autophosphorylation	  is	  always	  trans	  with	  the	  P4	  domain	  of	  one	  subunit	  phosphorylating	  the	  neighboring	  subunit’s	  P1	  domain111.	  An	  NMR	  study	  also	  hypothesized	  that	  the	  P1	  domain	  may	  have	  several	  binding	  modes	  with	  the	  P3	  and	  P4	  domains	  that	  help	  to	  limit	  the	  motion	  of	  the	  P1	  domain112.	  One	  possible	  scenario	  is	  that	  receptors	  in	  the	  ultra-­‐stable	  population	  interact	  with	  CheA	  differently	  than	  receptors	  in	  the	  quasi-­‐stable	  population.	  Through	  some	  unknown	  mechanism,	  CheA	  subunits	  interacting	  with	  ultra-­‐stable	  receptors	  adopt	  a	  conformation	  that	  constrains	  the	  P1-­‐P2	  domains	  and	  their	  linkers,	  making	  them	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less	  susceptible	  to	  proteolysis.	  An	  alternative	  hypothesis	  is	  that	  the	  quasi-­‐stable	  arrays	  are	  more	  dynamic	  and	  molecular	  motions	  within	  these	  arrays	  expose	  the	  linkers	  to	  proteolysis.	  
The	  Symmetry	  of	  CheA	  Proteolysis	  and	  Regions	  of	  Differential	  Stability.	  The	  results	  discussed	  thus	  far	  have	  not	  addressed	  the	  symmetry	  of	  CheA	  proteolysis.	  To	  address	  this	  possibility,	  CheA	  subunits	  in	  a	  homodimer	  were	  chemically	  cross-­‐linked	  together	  before	  denaturation.	  These	  experiments	  reveal	  that	  the	  major	  crosslinking	  product	  is	  two	  full-­‐length	  CheA	  subunits.	  Quantifying	  the	  density	  of	  the	  cross-­‐linked	  CheA	  bands	  yields	  a	  decay	  profile	  that	  is	  virtually	  indistinguishable	  from	  kinase	  activity	  decay	  profiles	  indicating	  that	  most	  of	  the	  full-­‐length	  CheA	  subnits	  in	  the	  array	  are	  symmetric	  dimers.	  A	  number	  of	  lower	  molecular	  weight	  dimers	  are	  observed	  in	  this	  experiment.	  Unfortunately,	  these	  lower	  weight	  bands	  could	  not	  be	  assigned	  to	  the	  P1-­‐P2	  or	  P2-­‐P3	  degradation	  fragments	  of	  CheA.	  Despite	  this	  shortcoming,	  these	  results	  indicate	  that	  typically,	  both	  CheA	  subunits	  are	  proteolyzed	  or	  neither	  CheA	  subunit	  is	  proteolyzed.	  Instead,	  these	  results	  agree	  with	  the	  earlier	  proposal	  that	  CheA	  subunits	  in	  ultra-­‐stable	  arrays	  are	  sterically	  protected	  from	  proteolysis	  while	  CheA	  subunits	  in	  quasi-­‐stable	  arrays	  are	  susceptible	  to	  it.	  	  
Ultra-­stable	  Populations	  are	  Sterically	  Protected	  From	  Proteolysis.	  To	  validate	  this	  hypothesis	  of	  steric	  from	  protection	  and	  also	  challenge	  the	  ultra-­‐stable	  region	  of	  the	  array,	  3	  nM	  trypsin	  was	  added	  to	  arrays	  before	  aging.	  Impressively,	  trypsin	  rapidly	  degrades	  the	  quasi-­‐stable	  population	  in	  a	  matter	  of	  hours,	  but	  barely	  degrades	  the	  ultra-­‐stable	  population	  even	  after	  5	  days.	  A	  small	  reduction	  in	  the	  size	  of	  the	  ultra-­‐stable	  population	  is	  observed	  (0.39	  compared	  to	  0.48,	  Table	  5.2).	  However,	  this	  modest	  reduction	  is	  within	  error	  of	  the	  non-­‐trypsinized	  samples.	  Ultra-­‐stable	  arrays	  also	  retain	  their	  sensitivity	  to	  attractant	  throughout	  this	  experiment	  suggesting	  that	  these	  arrays	  are	  fully	  functional	  even	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with	  the	  added	  trypsin.	  Collectively	  these	  observations	  corroborate	  that	  the	  source	  of	  decay	  for	  the	  quasi-­‐stable	  population	  is	  proteolysis	  and	  further	  indicate	  that	  the	  ultra-­‐stable	  population	  is	  protected	  from	  proteolysis.	  
A	  Mosaic	  Model	  of	  Chemosensory	  Arrays.	  One	  model	  for	  explaining	  these	  data	  would	  be	  that	  the	  quasi-­‐stable	  and	  ultra-­‐stable	  populations	  are	  different	  regions	  of	  the	  same	  array.	  Recent	  modeling	  and	  experimental	  studies	  have	  indicated	  that	  receptors	  form	  strongly	  coupled	  neighborhoods	  where	  all	  of	  the	  receptors	  in	  the	  neighborhood	  signal	  together113.	  Interspersed	  with	  these	  strongly	  coupled	  neighborhoods	  are	  weakly	  coupled	  neighborhoods.	  Cryo-­‐EM	  studies	  have	  corroborated	  these	  findings	  by	  showing	  that	  the	  lateral	  density	  of	  receptors	  in	  an	  array	  is	  not	  uniform	  but	  rather	  divided	  between	  less	  ordered	  and	  more	  ordered	  regions	  of	  receptors	  (Figure	  5.11)106.	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the	  same	  interconnectivity.	  Indeed,	  we	  observe	  a	  near	  doubling	  of	  the	  Hill	  coefficient	  of	  the	  array	  once	  the	  quasi-­‐stable	  population	  has	  decayed	  providing	  direct	  experimental	  evidence	  of	  the	  extra	  interconnectivity	  between	  components	  in	  ultra-­‐stable	  regions	  of	  the	  array.	  To	  directly	  explore	  the	  possibility	  that	  ultra-­‐stable	  regions	  of	  the	  array	  are	  more	  ordered	  than	  quasi-­‐stable	  regions,	  a	  small	  density	  of	  chemical	  defects	  was	  introduced	  into	  the	  array	  prior	  to	  array	  aging.	  Gratifyingly,	  labeling	  just	  2%	  of	  the	  total	  receptors	  with	  a	  bulky	  fluorophore	  is	  sufficient	  to	  eliminate	  the	  ultra-­‐stable	  population.	  After	  5	  days	  arrays	  have	  decayed	  to	  almost	  no	  activity	  and	  fit	  parameters	  suggests	  that	  >90%	  of	  the	  array	  is	  quasi-­‐stable	  rather	  than	  ultra-­‐stable.	  Addition	  of	  more	  label	  (6%,	  50%)	  causes	  a	  larger	  fraction	  of	  the	  array	  to	  degrade	  and	  at	  an	  even	  faster	  rate.	  	  These	  results	  suggest	  that	  ultra-­‐stability	  requires	  a	  highly	  interconnected	  array	  with	  a	  high	  degree	  of	  order	  between	  the	  assembled	  components.	  Even	  a	  small	  density	  of	  defects	  in	  these	  ultra-­‐stable	  regions	  causes	  a	  significant	  loss	  in	  stability.	  	  Collectively	  these	  results	  support	  a	  mosaic	  model	  of	  chemosensory	  arrays	  where	  an	  array	  is	  composed	  of	  equal	  populations	  of	  ultra-­‐stable	  and	  quasi-­‐stable	  regions	  (Figure	  5.11B).	  These	  regions	  are	  interspersed	  throughout	  the	  array	  and	  have	  different	  degrees	  of	  order	  and	  stability.	  Having	  the	  ability	  to	  modulate	  the	  stability	  of	  chemosensory	  arrays	  could	  provide	  several	  noteworthy	  advantages	  to	  bacteria.	  As	  previously	  mentioned,	  in	  nutrient	  poor	  environments	  where	  robust	  chemosensing	  is	  a	  necessity	  and	  the	  energy	  required	  to	  continually	  regenerate	  a	  large	  protein	  array	  is	  in	  short	  supply,	  bacteria	  could	  increase	  the	  order	  and	  stability	  of	  their	  arrays.	  One	  cryo-­‐EM	  has	  demonstrated	  that	  in	  nutrient	  poor	  environments	  bacteria	  do	  indeed	  decrease	  the	  spacing	  between	  receptors	  in	  their	  arrays,	  perhaps	  suggesting	  that	  their	  order	  is	  all	  increased106.	  An	  added	  advantage	  of	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Chapter	  6	  –	  Conclusions	  and	  Future	  Work	  on	  Bacterial	  Chemosensory	  Arrays	  
Introduction.	  The	  second	  part	  of	  this	  work	  has	  focused	  on	  characterizing	  the	  remarkable	  ultra-­‐stability	  exhibited	  by	  bacterial	  chemosensory	  arrays	  and	  exploring	  the	  origin	  of	  ultra-­‐stability	  in	  detail.	  The	  lifetime	  of	  ultra-­‐stable	  arrays	  and	  the	  kinetics	  of	  their	  decay	  in	  vitro	  were	  examined	  by	  following	  changes	  in	  kinase	  activity	  as	  well	  as	  changes	  in	  the	  stoichiometry	  of	  array	  components,	  revealing	  that	  the	  decay	  is	  correlated	  with	  proteolysis	  of	  CheA.	  The	  molecular	  basis	  of	  ultra-­‐stability	  was	  investigated	  by	  measuring	  changes	  in	  the	  cooperativity	  of	  arrays	  as	  they	  aged	  and	  also	  determining	  the	  effect	  of	  engineered	  defects	  on	  array	  stability.	  Our	  results	  show	  that	  the	  arrays	  are	  composed	  of	  two	  different	  stable	  populations:	  quasi-­‐	  and	  ultra-­‐stable.	  Impressively,	  ultra-­‐stable	  arrays	  have	  significantly	  higher	  Hill	  coefficients	  than	  the	  quasi-­‐stable	  arrays.	  Moreover,	  the	  introduction	  of	  even	  a	  low	  density	  of	  defects	  into	  the	  array	  is	  sufficient	  to	  disrupt	  the	  ultra-­‐stable	  population.	  This	  study	  proposes	  that	  arrays	  are	  not	  perfectly	  uniform,	  but	  are	  rather	  mosaics	  consisting	  of	  highly	  ordered	  regions	  of	  array	  interspersed	  with	  less	  ordered	  regions	  of	  array.	  The	  objective	  of	  this	  section	  is	  to	  summarize	  the	  results	  presented	  thus	  far	  and	  suggest	  future	  work	  for	  refining	  the	  mosaic	  model.	  
Conclusions:	  Chemosensory	  arrays	  are	  highly	  stable	  mosaics	  consisting	  of	  quasi-­stable	  
and	  ultra-­stable	  regions	  with	  different	  order,	  interconnectivity,	  stability,	  and	  cooperativity.	  Erbse	  and	  Falke	  first	  demonstrated	  that	  chemosensory	  arrays	  are	  ultra-­‐stable	  in	  
vitro92.	  They	  proposed	  that	  the	  significant	  interconnectivity	  between	  components	  may	  be	  the	  origin	  of	  ultra-­‐stability.	  However,	  their	  study	  did	  not	  determine	  the	  full	  lifetime	  of	  chemosensory	  arrays	  and	  also	  did	  not	  validate	  their	  proposed	  model.	  	  The	  lifetime	  of	  chemosensory	  arrays	  and	  the	  origin	  of	  their	  ultra-­‐stability	  were	  characterized	  in	  this	  study.	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The	  results	  demonstrate	  that	  chemosensory	  arrays	  have	  two	  stable	  populations:	  quasi-­‐stable	  with	  a	  lifetime	  of	  29	  ±	  9	  hours	  and	  ultra-­‐stable	  with	  a	  lifetime	  of	  457	  ±	  57	  hours.	  The	  source	  of	  decay	  is	  proteolysis	  of	  CheA	  homodimers,	  initially	  at	  the	  flexible	  linkers	  between	  P1-­‐P2	  and	  P2-­‐P3	  but	  eventually	  at	  other	  unidentified	  sites	  as	  well.	  Addition	  of	  exogenous	  protease	  increases	  the	  rate	  of	  degradation	  of	  the	  quasi-­‐stable	  population.	  Notably,	  this	  initial	  proteolysis	  at	  the	  linker	  regions	  of	  CheA	  is	  symmetric	  with	  both	  subunits	  being	  degraded—products	  with	  only	  one	  subunit	  proteolyzed	  were	  not	  detected.	  Collectively	  all	  of	  these	  data	  suggest	  that	  arrays	  contain	  two	  distinctly	  different	  populations.	  Since	  degradation	  was	  faster	  in	  the	  quasi-­‐stable	  population,	  this	  study	  proposed	  that	  quasi-­‐stable	  arrays	  are	  less	  ordered,	  more	  accessible	  to	  protease,	  and	  potentially	  less	  cooperative	  while	  ultra-­‐stable	  arrays	  are	  more	  ordered,	  less	  accessible	  to	  protease	  and	  more	  cooperative.	  To	  test	  this	  hypothesis	  the	  Hill	  coefficient	  of	  arrays	  was	  measured	  before	  and	  after	  aging.	  Remarkably,	  ultra-­‐stable	  arrays	  are	  nearly	  two	  fold	  more	  cooperative	  than	  their	  quasi-­‐stable	  counterparts.	  This	  hypothesis	  was	  further	  validated	  by	  demonstrating	  that	  there	  is	  a	  direct	  relationship	  between	  array	  order	  and	  stability	  by	  introducing	  various	  levels	  of	  chemically	  engineered	  defects	  into	  the	  array.	  	  	   The	  findings	  here	  support	  a	  model	  where	  chemosensory	  arrays	  are	  not	  uniform	  but	  rather	  consist	  of	  interspersed	  regions	  of	  less	  ordered,	  quasi-­‐stable	  regions	  and	  more	  ordered,	  ultra-­‐stable	  regions.	  The	  higher	  degree	  of	  order	  allows	  for	  extra	  interconnectivity	  between	  components	  and	  makes	  the	  ultra-­‐stable	  regions	  more	  cooperative	  and	  more	  stable.	  These	  findings	  are	  corroborated	  by	  modeling	  data,	  which	  suggest	  that	  neighborhoods	  of	  >20	  receptor	  dimers	  couple	  tightly	  together	  and	  signal	  as	  a	  team113,	  114.	  A	  cryo-­‐EM	  study	  has	  also	  directly	  observed	  that	  chemosensory	  arrays	  contain	  areas	  of	  high	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receptor	  order	  and	  areas	  of	  lower	  receptor	  order	  presumably	  referring	  to	  the	  ultra-­‐stable	  and	  quasi-­‐stable	  populations	  respectively106.	  Furthermore,	  the	  highly	  ordered	  regions	  are	  more	  prevalent	  when	  bacteria	  are	  grown	  in	  nutrient	  poor	  media	  and	  less	  prevalent	  when	  grown	  in	  rich	  media.	  Together	  these	  data	  suggest	  that	  bacteria	  can	  regulate	  the	  order	  and	  interconnectivity	  of	  arrays	  to	  modulate	  their	  stability	  and	  cooperativity.	  	  	   Proposed	  Future	  Studies.	  Future	  work	  on	  the	  stability	  of	  chemosensory	  may	  pursue	  a	  number	  of	  directions.	  First,	  the	  methylation	  sites	  on	  MCPs	  have	  been	  extensively	  characterized	  for	  their	  ability	  to	  modulate	  the	  cooperativity	  of	  the	  array75,	  91.	  In	  Tsr	  in	  particular,	  the	  Hill	  coefficient	  of	  fully	  unmethylated	  receptors	  is	  1.7	  while	  the	  coefficient	  for	  the	  fully	  methylated	  receptor	  is	  6.8.	  If	  the	  hypothesis	  presented	  here	  is	  correct,	  using	  fully	  methylated	  receptors	  instead	  of	  the	  partially	  methylated	  receptors	  used	  in	  this	  study	  may	  increase	  the	  stability	  of	  the	  array,	  perhaps	  by	  increasing	  the	  fraction	  of	  the	  array	  in	  ultra-­‐stable	  mosaics,	  or	  by	  further	  increasing	  the	  stability	  of	  the	  ultra-­‐stable	  mosaics.	  Using	  unmethylated	  receptors	  should	  produce	  a	  corresponding	  drop	  in	  stability.	  	  These	  results	  would	  certainly	  strengthen	  the	  model	  and	  also	  propose	  a	  direct	  means	  through	  which	  bacteria	  can	  tailor	  the	  stability	  of	  their	  arrays	  to	  the	  environment.	  Second,	  the	  findings	  in	  this	  study	  cannot	  draw	  any	  conclusions	  regarding	  the	  size	  or	  the	  nature	  of	  the	  imperfections	  in	  quasi-­‐stable	  array.	  Conflicting	  cryo-­‐EM	  reports	  have	  surfaced	  on	  this	  topic.	  One	  study	  reports	  large	  scale	  changes	  in	  the	  density	  and	  organization	  of	  receptors106.	  The	  other	  study	  does	  not	  observe	  these	  large	  scale	  changes	  and	  proposes	  that	  much	  smaller	  nanometer	  scale	  changes	  are	  occurring87.	  Performing	  cryo-­‐EM	  on	  the	  reconstituted	  inner	  membranes	  arrays	  to	  identify	  the	  scale	  of	  the	  imperfections	  could	  help	  clarify	  this	  disparity.	  Moreover,	  if	  the	  changes	  are	  large	  enough	  to	  see,	  comparing	  the	  relative	  area	  of	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well	  ordered	  to	  less	  ordered	  regions	  could	  confirm	  the	  roughly	  50:50	  split	  shown	  in	  this	  study.	  Third,	  the	  large	  disparity	  between	  array	  stability	  in	  vivo	  and	  in	  vitro	  suggests	  that	  the	  
in	  vivo	  measurements	  are	  an	  artifact	  of	  the	  fluorescent	  fusion	  proteins	  used,	  or	  there	  is	  a	  protease	  or	  chaperone	  that	  actively	  degrades	  or	  disassembles	  the	  array	  in	  vivo.	  Studies	  of	  exchange	  dynamics	  of	  CheA	  in	  vivo	  have	  suggested	  that	  CheA	  is	  stably	  integrated	  into	  the	  array	  for	  a	  matter	  of	  minutes100.	  This	  unknown	  molecule	  may	  be	  purified	  away	  during	  the	  membrane	  preparation	  process	  and	  provide	  a	  reasonable	  explanation	  as	  to	  the	  large	  disparity	  between	  array	  stability	  in	  vivo	  and	  in	  vitro.	  One	  potential	  candidate	  for	  this	  unknown	  degradation	  machinery	  is	  the	  unfoldase/protease	  combination	  ClpXP.	  Previous	  studies	  have	  identified	  that	  CheW	  contains	  a	  ClpX	  binding	  site	  and	  ClpXP	  knockout	  strains	  have	  significantly	  higher	  levels	  of	  cytosolic	  CheW115,	  116.	  These	  observations	  suggest	  that	  ClpXP	  may	  be	  a	  good	  starting	  point	  in	  the	  search	  for	  array	  disassembly	  machinery.	  Simply	  adding	  purified	  ClpXP	  to	  arrays	  in	  vitro	  could	  immediately	  clarify	  if	  this	  molecule	  is	  responsible	  for	  the	  reduced	  stability	  of	  arrays	  in	  vivo.	  Fourth,	  the	  general	  prevalence	  of	  ultra-­‐stability	  in	  chemosensory	  arrays	  has	  not	  been	  explored.	  The	  two	  studies	  conducted	  on	  the	  stability	  of	  arrays	  have	  only	  looked	  at	  arrays	  from	  E.	  coli	  and	  S.	  typhimurium92.	  The	  ultra-­‐stability	  observed	  in	  this	  study	  could	  be	  a	  special	  feature	  of	  these	  systems	  or	  could	  be	  widespread	  in	  all	  prokaryotes.	  One	  cryo-­‐EM	  has	  already	  indicated	  that	  the	  hexagonal	  architecture	  of	  these	  arrays	  is	  widespread	  and	  provides	  a	  tantalizing	  clue	  that	  ultra-­‐stability	  may	  also	  be	  conserved87.	  	  	   Collectively	  these	  studies	  would	  help	  refine	  the	  proposed	  model	  of	  ultra-­‐stability.	  Moreover,	  these	  studies	  would	  also	  help	  reconcile	  a	  number	  of	  current	  disparities	  in	  the	  literature	  regarding	  the	  organization	  of	  chemosensory	  arrays	  and	  their	  dynamics	  in	  vivo.	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